FINAL PROGRAM

VIENNA AUSTRIA JUNE 11 – 14 2015

e h a w e b . o r g 3

TA B L E O F C O N T E N T SWORDS OF WELCOME 4SpOnSORS

Corporate Sponsors 7Sponsors & Exhibitors 20th Congress of EHA 9

EHA

About EHA 13EHA Committees and Units 14Future Congresses & Meetings 16

COnGRESS ORGAnIZATIOn

Scientific Program Committee & Advisory Board 19Abstract Reviewers 20Education Book Reviewers 23Organizers 23

AWARDS

Travel Grant Winners 27José Carreras Lecture 28Jean Bernard Lifetime Achievement Award 28Fellowships Winners 29

KEY InFORMATIOn

Congress information 33Scientific information 35General information 37Transportation in Vienna 38

pROGRAM OVERVIEW

Program at a glance 42About the Congress Program 43What’s new this year? 43CME accreditation 44Hematology Curriculum 45Program overview per day 46Advocacy Track 54Early Career Track 55

COnGRESS pROGRAM

Thursday, June 11 61Friday, June 12 81Saturday, June 13 119Sunday, June 14 161

E-pOSTERS 177InDEX

Speaker & disclosure index 227Abstract author index 236Late breaking author index 300

FLOOR pLAnS

Floor Plan Reed Messe 306

Floor Plan Exhibition 308

INNOVATION, COLLABORATION & CELEBRATIONIt is with great pleasure that we welcome you to the 20th

Congress of the European Hematology Association (EHA).This year is a special year for EHA; we introduce an innovatedcongress program, we continue important collaborations andwe celebrate two important occasions. The EHA Board, andall EHA committees involved in the congress are happy towelcome you to Vienna!

InnovationThe congress program is tailored to meet the needs of thelarge variety of specialties and fields of interest and has beencompiled by the Scientific Program Committee and itsAdvisory Board, chaired by David Grimwade (King's CollegeLondon, United Kingdom).

We are proud to present you with a completely redesignedprogram. The new program aims to bring you more basicscience, while maintaining the strong clinical focus of theEHA Congress. We have introduced Basic-Science-in-Focusas well Laboratory-Diagnosis-in-Focus sessions. Thesetopics are clearly marked in the congress program. Anotherimportant change is the integration of EHA Scientific WorkingGroup sessions into the congress program, providing

primetime slots for the results and discussions from theseEHA umbrella clinical and scientific networks.The poster session will look a bit different as well; more timewill be dedicated to the important research presented there.Some will be formally presented by the authors in traditionalposter walks, while others will be available through E-posterscreens, allowing visitors to browse through them at theirleisure.

Also, the 20th Congress features the launch of EHA TV, anonline TV channel for out-of-session content and recordedlive in the EHA Theater. Drop by in the studio to watch therecording of EHA News (the daily news programs), theHEMtalks (inspirational non-scientific hematology relatedpresentations) or to join in on discussions with key opinionleaders. There will be a full program of recorded and non-recorded sessions and events. We hope you will enjoy thisadditional congress program.

Finally, after the 20th congress a large collection of congressmaterials will be available on the EHA Learning Center, suchas webcasts, podcasts, the abstract and education book,posters and EHA TV recordings. Drop by to re-visit yourpersonal highlights of this year’s congress.Download the mobile app, browse through the new program,create your personal congress agenda, watch EHA TV onyour mobile and tablet, and enjoy the 20th Congress of EHA.

CollaborationEHA is a networking organization that brings togetherstakeholders from all areas of hematology, from the researchlaboratory to the design of treatment, and everyday patientmanagement, involving all health care professionals,European and National authorities, patient advocacy groupsand industrial partners. EHA as a platform for disseminatingresults is demonstrated by this year’s new joint sessions. Thesession on European Union funded projects will highlight theresults and importance of two European research and trainingconsortia. The significance of such projects cannot beunderestimated, especially in the light of promoting andfacilitating European hematology research.

A special joint symposium with the Turkish Society ofHematology and the Indian Society of Haematology andBlood Transfusion will demonstrate the juxtaposition betweenEurope and the respective countries where it comes togenerics and biosimilars. Both Turkey and India have an

W O R D S O F W E L C O M EW O R D S O F W E L C O M E

4

e h a w e b . o r g 5

interesting environment with respect to legislation andreimbursement policies for research on and the production ofgenerics and biosimilars. Also during this congress the Advocacy Track will beorganized again. The alliance between EHA and the patientorganizations has shaped a number of sessions focused onadvocacy and lobbying. Room Strauss 2 is fully dedicated tothe Advocacy Track on Saturday, with different sessionsfocusing on patient advocacy, doctor / patientcommunication with ESH, and EHA’s research agenda.

CelebrationThe 20th anniversary of the Annual Congress and thecentennial edition of Haematologica are excellent reasons fordecorating the congress with some celebratory activitieswithout distracting from the scientific and educational core.

Firstly, EHA would like to offer all members of the Associationa copy of Fresh Blood - the story of EHA and developmentsin European hematology. The last 25 years of the history ofthe Association, the congress and its activities have beenmapped out and discussed with the founding fathers, pastand current leaders, and strong supporters both young andold.

Secondly, the Opening Ceremony will have a very specialViennese flavor so we hope to welcome you there. Moreover,for a real taste of Vienna attend the Networking Reception inthe Rathaus on Saturday evening and join us for a piece ofapfel strudel and Sacher Torte on Sunday afternoon at theend of the scientific program and closing of the congress.

Thirdly, the centennial volume of Haematologica will becelebrated in a dedicated session on Saturday. The editor-in-chief, Jan Cools will welcome you and chair the sessionwhich contains some important basic research which hasbeen submitted to the journal recently. In your congress bagyou will find a special edition of Haematologica celebrating its100th volume.

Finally, to compensate for the cake, the food and celebratorydrinks join us for the first EHA Congress Run. We are excitedabout this healthy addition to the congress, especiallybecause the funds raised will be donated to the EHAResearch Grant Fund. Enjoy yourself in a healthy way andsupport hematology research in Europe and beyond.

ABSTRACT PROGRAM & OTHER HIGHLIGHTS OF THEPROGRAMAt EHA we like round numbers, so we are very happy with the2200 submitted abstracts for the program. After a thoroughreview by the abstract reviewers exactly 262 abstracts areselected for a presentation in one of the 37 simultaneoussessions covering all fields of hematology.We have also introduced the late breaking procedure for datathat was not available at the time of the regular submissiondeadline. The most exciting results have been selected andtwo oral sessions have been composed. You are invited tothe late breaking abstract sessions on Sunday, June 14 from10:45 - 11:30 (Room Strauss 1) and 11:45 - 12:45 (Room A7).

Next to the abovementioned sessions and highlights wewould like to remind you of some special sessions for you:• Opening Ceremony (Friday)• José Carreras Award & Lecture (Friday)• Presidential Symposium (Friday)• Plenary Sessions (Saturday & Sunday)• EHA Business Meeting (Sunday, EHA Members only)

All of the above together will make this another busy yetenjoyable congress, particularly in such an amazing city likeVienna! We look forward to meeting you in the varioussessions, or at the Networking Reception.

Don’t forget to play the grand piano in the entrance hall!

With kind regards

Christine Chomienne David GrimwadeEHA President Chair Scientific

Program Committee

T-cell engagement strategies for ALL: examining the emerging data

The 20th Congress of the European Hematology Association

ProgrammeChair:

Welcome and introduction

Contemporary concepts in ALL: uncovering clonal evolution

Understanding the role of minimal residual disease (MRD)

The bispecific antibody construct blinatumomab in ALL:

Chimeric antigen-receptor (CAR) T cells in ALL

The changing landscape of treatment: impact on selection of patients for transplant

Panel discussion

examining the emerging data -cell TT-cell engagement strategies for ALL:

examining the emerging data -cell engagement strategies for ALL:

examining the emerging data -cell engagement strategies for ALL:

examining the emerging data -cell engagement strategies for ALL:

Lehar 1+2, Reed Messe WThursday 11 June 2015, 13.30–15.30

elcome and intrW

Dieter HoelzerChair: ogrammePr

Dieter Hoelzer

einLehar 1+2, Reed Messe WThursday 11 June 2015, 13.30–15.30

oductionelcome and intr

, GermanyDieter Hoelzer

ogramme

, GermanyDieter Hoelzer

Thursday 11 June 2015, 13.30–15.30

Charles Mullighan, USAContemporary concepts in ALL: uncovering clonal evolution

Understanding the rMonika Brüg

The bispecific antibody construct blinatumomab in ALL:

Monika Brüg

opp, GMax T Topp, Germany

Charles Mullighan, USAContemporary concepts in ALL: uncovering clonal evolution

esidual disease (MRD)ole of minimal rUnderstanding the r gemann Germany

fic an

g

opp, Germany

Contemporary concepts in ALL: uncovering clonal evolution

esidual disease (MRD)

scan the code abovethis symposium please For information about

scan the code abovethis symposium please For information about

Panel discussion

nelissen, The NetherlandsJan Corpatients for transplantThe changing landscape of tr

Martin Pule, UKChimeric antigen-r

Panel discussion

nelissen, The Netherlandspatients for transplant

eatment: impact on selection of The changing landscape of tr

Martin Pule, UKeceptor (CAR) T ce Chimeric antigen-r

eatment: impact on selection of

lls in AL

CH-6300 ZugDammstrasse 23

Amgen (Eur

CH-6300 ZugDammstrasse 23

ope) GmbHAmgen (Eur

Blinatumomab is an investigational pr

oductBlinatumomab is an investigational pr

EUHQ-NP-103-0415-104800a. 04.2015© 2015 Amgen Inc. All rights r

.amgen.comwww

CH-6300 Zug

EUHQ-NP-103-0415-104800a. 04.2015eserved. © 2015 Amgen Inc. All rights r

.amgen.comSwitzerland

CH-6300 Zug

e h a w e b . o r g 7

C O R P O R AT E S P O N S O R S 2 0 1 5The European Hematology Association wishes to express its gratitude to the following sponsors and exhibitors:

platinum

Contributors

Gold

Silver

Bronze

Charting new depths in the treatment of multiple myelomaThursday 11 June 2015, 16.15–18.15 Room C2, Messe Wien, Vienna, Austria

ProgrammeChair: Jesús San Miguel, Spain

Welcome and introductionJesús San Miguel, Spain

Choosing the right course – identifying myeloma defining events and acting accordingly Faith Davies, USA

Navigating the heterogeneity of myeloma – how can we individualise treatment and monitor outcomes most effectively? Jesús San Miguel, Spain

What’s on our radar – strategies for achieving the deepest and most durable responses in newly diagnosed multiple myelomaHermann Einsele, Germany

Charting new depths in the treatment of relapsed multiple myeloma Andrzej Jakubowiak, USA

Panel discussion All

Amgen (Europe) GmbH, Dammstrasse 23, CH-6300 Zug, Switzerland. www.amgen.com

© 2015 Amgen Inc. All rights reserved. MRC-GCARF-104206 April 2015 EUHQ-NP-CARF-0415-104596

e h a w e b . o r g 9

� Adaptive Biotechnologies� Abbvie� Adaptive Biotechnologies� Alexion Pharmaceuticals� American Society for Hematology� Amgen� Amyloidosis Foundation� ApoPharma� Ariad� Asuragan� Basilea� Baxter� Binding Site� Bristol-Myers Squibb� Celgene� CTI life science� Cytocell� DNA Diagnostic A/S � Elsevier� Epgonline� ESLHO foundation� European commision� European LeukemiaNet� European School of Haematology� F. Hoffmann - La Roche Ltd.� Genection� Genzyme� Gilead� Illumina� Imedex� Infinity Pharmacuticals� Informa Healthcare� International Myeloma Foundation � Invivoscribe� ITP Support Assocation� Janssen� Japanese Society of Hematology� LabPMM� Lipomed� Lymphoma Coalition� MDS� MDS Alliance, LHRM� MDS diagnosis� Myeloma Patients Europe� Novartis Oncology� Novella Clinical

� Patient Advocates Foundation� Pfizer� prIME Oncology� Qiagen� Raindance� Sandoz� Shire Pharmaceuticals Limited� SkylineDX� Sultan bin Khalifa international thalassemia Award� Sunesis � Takeda� Teleflex� Teva� Thalassaemia International Federation� The Triumph group� Turkish Society of Hematology� West Medica� Wisepress

SPONSORS & EXHIBITORS 20 TH CONGRESS OF EHA (as of May 1)

Iclusig®� (ponatinib)

Unlock effi cacy for resistant or intolerant CML and Ph+ ALL patients

Copyright © 2015 ARIAD Pharmaceuticals, Inc. All rights reserved. Date of preparation: April 2015; EU/ICLG/15/0026.

1 Iclusig (ponatinib). Latest Summary of Product Characteristics (February 2015). Iclusig® 15 mg fi lm-coated tablets / Iclusig® 45 mg fi lm-coated tabletsActive substance: ponatinib

� This medicinal product is subject to additional monitoring. This will allow quick identifi cation of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the Summary of Product Characteristics for how to report adverse reactions. Please read the full Summary of Product Characteristics (SmPC) before prescribing Iclusig®. Qualitative and quantitative composition: Each fi lm-coated tablet contains 15 mg resp. 45 mg of ponatinib (as hydrochloride). Excipients with known effect: Each fi lm-coated tablet contains 40 mg of lactose monohydrate (Iclusig 15 mg) resp. 120 mg of lactose monohydrate (Iclusig 45 mg). Full list of excipients: Tablet core: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, colloidal anhydrous silica, magnesium stearate. Tablet coating: talc, macrogol 4000, poly(vinyl alcohol), titanium dioxide (E171). Therapeutic indications: Iclusig is indicated in adult patients with • chronic phase, accelerated phase, or blast phase chronic myeloid leukae-mia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. • Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. See section 4.2 of the SmPC for assessment of cardiovascular status prior to start of therapy and section 4.4 of the SmPC for situations where an alternative treatment may be considered. Contraindications: Hypersensitivity to the active substance or to any of the excipients. Undesirable effects: Very common adverse reactions (≥ 1/10): upper respiratory tract infection, anaemia, platelet count decreased, neutrophil count decreased, decreased appetite, insomnia, headache, dizziness, hypertension, dyspnoea, cough, abdominal pain, diarrhoea, vomiting, constipation, nausea, lipase increased, alanine aminotransferase increased, aspartate aminotransferase increased, rash, dry skin, bone pain, arthralgia, myalgia, pain in extremity, back pain, muscle spasms, fatigue, asthenia, oedema peripheral, pyrexia, pain. Common adverse reactions (≥ 1/100 to < 1/10): pneumonia, sepsis, folliculitis, pancytopenia, febrile neutropenia, white blood cell count decreased, dehydration, fl uid retention, hypocalcaemia, hyperglycaemia, hyperuricaemia, hypophosphataemia, hypertriglyceridaemia, hypokalaemia, weight decreased, cerebrovascular accident, cerebral infarction, neuropathy peripheral, lethargy, migraine, hyperaesthesia, hypoaesthesia, paraesthesia, transient ischaemic attack, vision blurred, dry eye, periorbital oedema, eyelid oedema, cardiac failure, myocardial infarction, cardiac failure congestive, coronary artery disease, angina pectoris, pericardial effusion, atrial fi brillation, ejection fraction decreased, peripheral arterial occlusive disease, peripheral ischaemia, peripheral artery stenosis, intermittent claudication, deep vein thrombosis, hot fl ush, fl ushing, pulmonary embolism, pleural effusion, epistaxis, dysphonia, pulmonary hypertension, pancreatitis, blood amylase increased, gastrooesophageal refl ux disease, stomatitis, dyspepsia, abdominal distension, abdominal discomfort, dry mouth, blood bilirubin increased, blood alkaline phosphatase increased, gamma-glutamyltransferase increased, rash pruritic, exfoliative rash, erythema, alopecia, pruritis, skin exfoliation, night sweats, hyperhidrosis, petechia, ecchymosis, pain of skin, dermatitis exfoliative, musculoskeletal pain, neck pain, musculoskeletal chest pain, erectile dysfunction, chills, infl uenza like illness, non-cardiac chest pain, mass, face oedema. Uncommon adverse reactions (≥ 1/1000 to < 1/100): tumour lysis syndrome, cerebral artery stenosis, retinal vein thrombosis, retinal vein occlusion, retinal artery occlusion, visual impairment, myocardial ischemia, acute coronary syndrome, cardiac discomfort, ischemic cardiomyopathy, arteriospasm coron-ary, left ventricular dysfunction, atrial fl utter, poor peripheral circulation, splenic infarction, embolism venous, venous thrombosis, gastric haemorrhage, hepatotoxicity, jaundice. Note to selected adverse reactions: Serious vascular occlusion has occurred in patients treated with Iclusig, including cardiovascular, cerebrovascular and peripheral vascular events, and venous thrombotic events. Myelosuppression was commonly reported in all patient populations. Warnings: Contains lactose. See the package leafl et for further information. Do not swallow the desiccant canister found in the bottle. See also published Summary of Product Characteristics for further information about warnings and precautions. General classifi cation for supply: Medicinal product subject to medical prescription (Austria: „Rezept- und apothekenpfl ichtig“). Pharmacotherapeutic group: antineoplastic agent, protein kinase inhibitor, ATC code: L01XE24 Marketing authorisation holder: ARIAD Pharma Ltd., Riverbridge House, Guildford Road, Leatherhead, Surrey KT22 9AD, United Kingdom. Further information: Please refer to the published Summary of Product Characteristics for detailed information about warnings and precautions for use, interactions, pregnancy and lactation, undesirable effects, as well as posology and method/duration of use. Status: 02/2015 Adverse events should be reported. Adverse events should also be reported to ARIAD immediately by phoning the EU universal free phone number 00-800-0002-7423.

Iclusig is an oral once-daily TKI indicated in adult patients Iclusig is an oral once-daily TKI indicated in adult patients Iclusig is an oral once-daily TKI indicated in adult patients with CML and Ph+ ALL11

CP, AP or BP-CML who:• Are resistant to dasatinib or nilotinib or• Are intolerant to dasatinib or nilotinib and for whom subsequent

treatment with imatinib is not clinically appropriate or• Have the T315I mutation

Ph+ ALL who:• Are resistant to dasatinib or• Are intolerant to dasatinib and for whom subsequent

treatment with imatinib is not clinically appropriate or• Have the T315I mutation

ABOUT EHA

Free and unlimited access

to the EHA Learning

Center

Discount on EHA Congress and all

other EHA events’ individual

registration fees

Monthly subscription to Haematologica

Access to EHA Membership

Directory

Access to the CV Passport

Online

Nomination and voting rights in the EHA Ballot EHA

Subscriptions

Eligibility to EHA Career Development

Grants

Eligibility to EHA Congress travel grants

ENJOY OUR MEMBERSHIP BENEFITS ALL YEAR ROUND

Become a member of EHA for 2015!

Login to “MyEHA” on the EHA website, select your fee and follow the instructions to successfully fi nalize your payment. Need help? Email membership@ehaweb.org or call the EHA Executive Offi ce at +31(0)70 3020 099.

ALREADY A MEMBER? RENEW YOUR MEMBERSHIP NOW!

Support our mission to promote excellence in patient care, research and education in hematology.

Join more than 4,000 members from over 100 countries worldwide and enjoy membership benefi ts that open opportunities for both professional and personal development within the fi eld of hematology.

BECOME A MEMBER!

Full Membership € 155 Junior Membership € 20 Health Care Affi liated Professional

Membership € 90 Emeritus Membership € 90

DISCOUNT

50%

FOR THE REMAINDER OF 2015

ON MEMBERSHIP FEES

NOW

e h a w e b . o r g 13

The European Hematology Association (EHA) is a non-profitscientific association that represents European medicalprofessionals with an active interest in hematology. TheAnnual Congress, organized in a major European City, offersthe opportunity to learn about new data from basic,translational and clinical research and gives access toknowledge that directly impacts the clinical practice. Not onlythe size of the congress increased over the years but also thefirst steps towards creating an education and careerdevelopment program were taken.

Educational needs are the focus of our continuing medicaleducation program. Not only through live events, but alsothrough the EHA Learning Center, a recently launched onlineplatform. EHA supports high quality science: we encourageresearch by creating a network and sharing knowledge.

EHA offers education and training and supports the careers ofof hematologists in Europe and travelling to Europe throughits fellowships and grants program. Different fellowships areavailable for basic, translational and clinical researchers bothin their early or advanced career.

As the largest organization of hematologists in Europe, EHAhas taken it upon itself to serve and further their politicalinterests. We advocate for you on the EU level for moreresearch funding, improved research environment and betteraccess to hematology care.

Information about all the activities of the Association can befound on the website: www.ehaweb.org.

A B O U T E H A

EXECUTIVE BOARDC Chomienne, France (President)T Green, United Kingdom (President Elect)U Jäger, Austria (Past President)J Sierra, Spain (Secretary)P Sonneveld, the Netherlands (Treasurer)

COUNCILORSA Brand, the NetherlandsD Bron, BelgiumA Engert, GermanyS Fröhling, GermanyD Grimwade, United KingdomS Izraeli, IsraelL Malcovati, ItalyM Muckenthaler, GermanyG Ossenkoppele, the NetherlandsF Rodeghiero, Italy

EUROPEAN BOARD FOR ACCREDITATION IN HEMATOLOGYA Tichelli, Switzerland (Chair)H Akan, TurkeyM Guenova, BulgariaD Loukopoulos, GreeceP Rebulla, ItalyI Roberts, United KingdomM Vilarmau, Spain

COMMUNICATION COMMITTEEA Hagenbeek, the Netherlands (Chair)C Chomienne, FranceJ Cools, BelgiumS Fröhling, GermanyT Green, United KingdomM Guenova, BulgariaC Lacombe, FranceE Macintyre, FranceS McCann, IrelandI Roberts, United Kingdom

CURRICULUM COMMITTEEC-H Toh, United Kingdom (Chair)A Almeida, PortugalP Fenaux, FranceM Guenova, BulgariaE Hellström-Lindberg, Sweden (ex-officio)M Liljeholm, SwedenS Modok, HungaryG Ossenkoppele, the Netherlands

EARLY CAREER ADVISORY GROUPA Ramsay, United KingdomAK Eisfeld, Germany/US

C Scharenberg, SwedenF McClanahan, United KingdomH Becker, GermanyM Isabel, PortugalM Gruber, Austria/USV Gaidzik, GermanyM Mraz, Czech Republic

EDUCATION COMMITTEER Foà, Italy (Chair)A Borkhardt, GermanyD Bron, BelgiumC Chomienne, FranceC Dufour, ItalyU Jäger, AustriaS McCann, IrelandG Ossenkoppele, the NetherlandsI Peake, United KingdomA Tichelli, SwitzerlandC-H Toh, United Kingdom

EHATOL UNITS McCann, Ireland (Chair)B Bain, United KingdomJ Burthem, United KingdomM Holmström, SwedenC McNamara, United KingdomM de Montalembert, FranceO Ozer, TurkeyH Serve, GermanyG Zini, Italy (Advisor)

EUROPEAN AFFAIRS COMMITTEEU Jäger, Austria (Chair)D Bron, BelgiumC Chomienne, FranceT Green, United KingdomA Hagenbeek, the Netherlands

FELLOWSHIPS AND GRANTS COMMITTEEM Muckenthaler, Germany (Chair)J Bourquin, SwitzerlandR Delwel, the NetherlandsJ Eikenboom, the NetherlandsS Fröhling, GermanyG Gaidano, ItalyR Handgretinger, GermanyT Holyoake, United KingdomE Macintyre, FranceV Sexl, Austria

FUNDRAISING AND SPONSOR COMMITTEEU Jäger, Austria (Chair)

14

E H A C O M M I T T E E S A N D U N I T S ( a s o f J u n e 2 0 1 4 )

A Engert, GermanyR Foà, ItalyS Fröhling, GermanyP Sonneveld, the NetherlandsF Rodeghiero, Italy

GOOD GOVERNANCE COMMITTEEW Fibbe, the Netherlands (Chair)T Barbui, ItalyA Borkhardt, GermanyL Degos, FranceL Malcovati, Italy

MEMBERSHIP COMMITTEEA Borkhardt, Germany (Chair)H Cavé, FranceJ C̆ermák, Czech RepublicJ Cools, BelgiumS Fröhling, GermanyF Prosper Cardoso, Spain

NOMINATION COMMITTEEI Touw, the Netherlands (Chair)C Camaschella, ItalyH Döhner, GermanyE Hellström-Lindberg, SwedenG Salles, France

REVIEW BOARDG Ossenkoppele, the Netherlands (Chair)MC Béné, FranceD Bron, BelgiumS Eichinger, AustriaG Gaidano, ItalyE Hellström-Lindberg, SwedenJ Palmblad, SwedenP Rebulla, ItalyA Urbano, Spain

SCIENTIFIC PROGRAM COMMITTEE 20TH CONGRESSD Grimwade, United Kingdom (Chair)E Angelucci, ItalyM Beksac, TurkeyA Brand, the NetherlandsR Delwel, the NetherlandsH Dombret, FranceS Eichinger, AustriaJ Eikenboom, the NetherlandsA Engert, GermanyA Hochhaus, GermanyS Karlsson, SwedenL Macintyre, FranceM Mateos, Spain

E Solary, FranceP Sonneveld, the NetherlandsK Stamatopoulos, GreeceS Stilgenbauer, GermanyA Sureda, Spain

LOCAL REPRESENTATIVE 20TH CONGRESSI Pabinger, Austria

SCIENTIFIC PROGRAM COMMITTEE ADVISORY BOARD20TH CONGRESS L Adès, FranceA Balduzzi, ItalyM de Bruijn, United KingdomA Fielding, United KingdomS Fröhling, GermanyK Grønbæk, DenmarkJ Janssen, the NetherlandsN Kröger, GermanyH Ludwig, AustriaC Moreno, SpainE Papaemmanuil, GreeceJA Perez-Simon, SpainJ Porter, United KingdomA Reiter, GermanyN Russell, United KingdomS Soverini, ItalyS Stanworth, United KingdomC-H Toh, United KingdomM van den Heuvel, the NetherlandsH Veelken, the Netherlands

SWG UNITP Sonneveld, the Netherlands (Chair)MC Béné, FranceM Dreyling, GermanyC Dufour, ItalyR Foà, ItalyD Grimwade, United KingdomA Iolascon, ItalyL Malcovati, ItalyG Ossenkoppele, the NetherlandsS-L Thein, United Kingdom

TRTH JOINT OVERSIGHT COMMITTEED Bodine, USAC Dunbar, USAD Grimwade, United KingdomU Jäger, AustriaJ Licht, USAD Neuberg, USA Advisory MemberJ Soulier, France

e h a w e b . o r g 15

2015CSH LEUKEMIA CONGRESS - EHA JOINT SYMPOSIUM &PLENARY LECTUREJuly 18, 2015Harbin, China

EHA-SWG SCIENTIFIC MEETING INTEGRATED APPROACHTO DEMANDING HEMATOLOGICAL DIAGNOSES, FROMMDS TO LEUKEMIASChairs: A Falanga and C Balduini September 10-12, 2015Barcelona, Spain

EHA-SWG SCIENTIFIC MEETING - HEMOSTASISIMBALANCE: CRITICAL ISSUES AND THERAPEUTICAPPROACHESChair: MC Béné September 18-20, 2015Barcelona, Spain

EHA - RUSSIAN ONCO-HEMATOLOGY SOCIETY - JOINTSYMPOSIUMOctober 22-23, 2015Moscow, Russian Federation

BEST OF EHA - ARGENTINIAN HEMATOLOGY CONGRESSOctober 25-26, 2015Mar del Plata, Argentina

EHA - INDIAN SOCIETY OF HAEMATOLOGY & BLOODTRANSFUSION - JOINT SYMPOSIUMNovember 5-8, 2015Bengaluru, India

EHA - KOREAN SOCIETY OF HEMATOLOGY - JOINTSYMPOSIUMNovember 6-7, 2015Teghu, Korea

EHA HEMATOLOGY TUTORIAL ON ANEMIA OF CHRONICDISEASE AND MDSChairs: Barbara Bain, David Bowen, Maria DomenicaCappellini, Günter WeissNovember 13-14, 2015Prague, Czech Republic

2016HEMATOLOGY TUTORIAL – EHA & INDIAN SOCIETY OFHAEMATOLOGY & BLOOD TRANSFUSIONJanuary 29-31, 2016Mumbai, India

5TH PAN-ARAB HEMATOLOGY CONGRESS - BEST OF EHAFebruary 11-13, 2016Cairo, Egypt

3RD RUSSIAN HEMATOLOGY SOCIETY CONGRESS - EHAJOINT SYMPOSIUMApril 14-16, 2016Moscow, Russian Federation

TRANSLATIONAL RESEARCH TRAINING IN HEMATOLOGY– SPRING COURSEMarch 11-18, 2016Milan, Italy

21ST CONGRESS OF THE EUROPEAN HEMATOLOGYASSOCIATIONJune 9-12, 2016Copenhagen, Denmark

16

F U T U R E E H A C O N G R E S S E S & M E E T I N G S

CONGRESSORGANIZATION

We want to transform the lives of cancer patients with breakthrough medicines.

For more information about ARIAD, visit www.ARIAD.com

Copyright © 2015 ARIAD Pharmaceuticals, Inc. All rights reserved. Date of preparation: April 2015; ICLG/CORP/15/0029

We want to transform the lives of cancer patients with breakthrough

19

SCIENTIFIC PROGRAM COMMITTEE D Grimwade, United Kingdom (Chair)E Angelucci, ItalyM Beksac, TurkeyA Brand, the NetherlandsR Delwel, the NetherlandsH Dombret, FranceS Eichinger, AustriaJ Eikenboom, the NetherlandsA Engert, GermanyA Hochhaus, GermanyS Karlsson, SwedenL Macintyre, FranceM Mateos, SpainE Solary, FranceP Sonneveld, the NetherlandsK Stamatopoulos, GreeceS Stilgenbauer, GermanyA Sureda, Spain

LOCAL REPRESENTATIVE I Pabinger, Austria

ADVISORY BOARDL Adès, FranceA Balduzzi, ItalyM de Bruijn, United KingdomA Fielding, United KingdomS Fröhling, GermanyK Grønbæk, DenmarkJ Janssen, the NetherlandsN Kröger, GermanyH Ludwig, AustriaC Moreno, SpainE Papaemmanuil, GreeceJA Perez-Simon, SpainJ Porter, United KingdomA Reiter, GermanyN Russell, United KingdomS Soverini, ItalyS Stanworth, United KingdomC-H Toh, United KingdomM van den Heuvel, the NetherlandsH Veelken, the Netherlands

e h a w e b . o r g 19

C O N G R E S S O R G A N I Z AT I O N

20

Adès L, FranceAleman B, the NetherlandsAngelucci E, ItalyAydinok Y, TurkeyBadens C, FranceBalduini C, ItalyBalduzzi A, ItalyBeishuizen A, the NetherlandsBeksac M, TurkeyBende R, the NetherlandsBernard O, FranceBierings M, the NetherlandsBlaise D, FranceBoda Z, HungaryBorchmann P, GermanyBorregaard N, DenmarkBourquin JP, SwitzerlandBowen D, United KingdomBrand A, the NetherlandsBreccia M, ItalyBrenner B, IsraelBriones J, SpainBrown P, DenmarkBruce L, United KingdomBrune M, SwedenCaballero D, SpainCaligaris-Cappio F, ItalyCampo E, SpainCastaman G, ItalyCervantes F, SpainCesaro S, ItalyChiorazzi N, USACilloni D, ItalyClark R, United KingdomCook G, United KingdomCools J, BelgiumCorradini p, ItalyCraddock C, United KingdomCurtis B, USACymbalista F, FranceD'amore F, DenmarkDawson M, Australiade Bruijn M, United Kingdomde Haas M, the NetherlandsDeaglio S, ItalyDelforge M, BelgiumDelwel R, the Netherlands

Dennis M, United KingdomDevine D, CanadaDimopoulos M, GreeceDöhner K, GermanyDokal I, United KingdomDombret H, FranceDorak MT, United KingdomDreger P, GermanyDreyling M, GermanyDuprez E, FranceEfficace F, ItalyEichinger S, AustriaEikenboom J, the NetherlandsEinsele H, GermanyEldering E, the NetherlandsElmaagacli A, GermanyEngert A, GermanyErnst T, GermanyEsteve J, SpainFederici A, ItalyFehse B, GermanyFenaux P, FranceFielding A, United KingdomFonseca R, USAForoni L, United KingdomFrey B, SwitzerlandFröhling S, GermanyFronkova E, Czech RepublicGarcia-Manero G, USAGarcia-Sanz R, SpainGarderet L, FranceGennery A, United KingdomGerming U, GermanyGibson B, United KingdomGisselbrecht C, FranceGobhrial I, USAGoker H, TurkeyGoodeve A, United KingdomGreenfield D, United KingdomGribben J, United KingdomGrønbæk K, DenmarkHaioun C, FranceHalkes CJ, the NetherlandsHalter J, SwitzerlandHansen JB, NorwayHarrison C, United KingdomHasselbalch H, Denmark

Hellström-Lindberg E, SwedenHill A, United KingdomHochhaus A, GermanyHöchsmann B, GermanyHoskin PJ, United KingdomHuang XJ, ChinaHughes T, AustraliaHuguet F, FranceHuisman MV, the NetherlandsHuntly B, United KingdomIzraeli S, IsraelJäger U, AustriaJansen J, the NetherlandsJantunen E, FinlandJilma B, AustriaKarlsson S, SwedenKastritis S, GreeceKim D, CanadaKindler T, GermanyKluin-Nelemans JC, the NetherlandsKouskoff V, United KingdomKremer Hovinga J, SwitzerlandKröger N, GermanyKuball JK, the NetherlandsKulasekararaj A, United KingdomLabar B, CroatiaLacombe C, FranceLange A, PolandLapidot T, IsraelLayton DM, United KingdomLe Blanc K, SwedenLe Coutre P, GermanyLisman T, the NetherlandsLo Celso C, United KingdomLo Coco F, ItalyLonial S, USALouache F, FranceLouw VJ, South AfricaLozano M, SpainLudwig H, AustriaLuminari S, ItalyMacintyre E, FranceMadrigal A, United KingdomMakris M, United KingdomMalcovati L, ItalyMalek S, USAManz M, Switzerland

A B S T R A C T R E V I E W E R SEHA would like to thank the following persons for their time and efforts reviewing abstracts for this Congress.

Martin-Subero JI, SpainMaschmeyer G, GermanyMateos M, SpainMayer J, Czech RepublicMcmullin MF, United KingdomMead A, United KingdomMellquist U, SwedenMeyer LH, GermanyMichallet M, FranceMilpied N, FranceMilsom M, GermanyMontagna D, ItalyMontillo M, ItalyMoorman A, United KingdomMoreno C, SpainMüller M, GermanyMumford A, United KingdomMusallam K, LebanonMusto P, ItalyMuus P, the NetherlandsNoizat-Pirenne F, FranceNoris M, ItalyNowak D, GermanyO'Dwyer M, IrelandOkur FV, TurkeyOlsson M, SwedenOppliger E, SwitzerlandPabinger I, AustriaPabst T, SwitzerlandPadron E, USAPadua R, FrancePapaemmanuil E, United KingdomPassweg J, SwitzerlandPerez-Simon JA, SpainPerotta S, ItalyPfreundschuh M, GermanyPlatzbecker U, GermanyPlesner T, DenmarkPlo I, FrancePonzoni M, Italy

Porter J, United KingdomPreudhomme C, FranceRadich J, USARambaldi A, ItalyRea D, FranceRees D, United KingdomReiter A, GermanyRezvani K, USARibera JM, SpainRivella S, Italy/USARoth MP, FranceRussell N, United KingdomRuutu T, FinlandSalek S, United KingdomSandset PM, NorwaySanz M, SpainSchlegelberger B, GermanySchmitz N, GermanySchnittger S, GermanySchouten H, the NetherlandsSeymour J, AustraliaSiebert R, GermanySierra J, SpainSimula MP, ItalySocié G, FranceSolary E, FranceSomervaille T, United KingdomSonneveld P, the NetherlandsSoulier J, FranceSoverini S, ItalySoysal T, TurkeySpencer A, AustraliaSpiekermann K, GermanySpyridonidis A, GreeceSrivastava A, IndiaStamatopoulos K, GreeceStanworth S, United KingdomStentoft J, DenmarkStilgenbauer S, GermanyStrahm B, Germany

Sureda A, United KingdomSutton LA, SwedenTam C, AustraliaTamburini J, Franceten Cate H, the NetherlandsTesio M, FranceThachil J, United KingdomTheilgaard K, DenmarkThiede C, GermanyThomas X, FranceThomas DA, USATichelli A, SwitzerlandToh CH, United KingdomTonon G, ItalyTreon S, USATrneny M, Czech RepublicUsala E, ItalyValk P, the Netherlandsvan de Donk N, the Netherlandsvan den Heuvel M, the Netherlandsvan der Reijden B, the Netherlandsvan der Velden V, the Netherlandsvan Etten R, USAVan Riet I, Belgiumvan Wijk R, the NetherlandsVannucchi A, ItalyVeelken H, the NetherlandsVellenga E, the NetherlandsViprakasit V, ThailandVitolo U, ItalyViviani S, Italyvon Mackensen S, GermanyWelte K, GermanyWilson W, USAWlodarski M, GermanyWoll PS, United KingdomYong K, United KingdomZinzani PL, ItalyZoi K, GreeceZweegman S, the Netherlands

e h a w e b . o r g 21

Dates: September 10-12, 2015Location: Barcelona, Spain

Organized by: EHA Scientifi c Working Group Leukemia diagnosis: morphology and fl ow cytometry

Chair: MC Béné

Co-chair: G Zini

Topics: Pre-analytical considerations Hematopoiesis, from progenitors to granulocytes

and monocytes, myeolodysplastic syndromes (MDS) and acute myeloid leukemia (AML)

Hematopoiesis, from progenitors to erytrhocytes and platelets, related disorders

Hematopoiesis, from progenitors to lymphocytes, chronic lymphocytic leukemia (CLL) and lymphoproliferative disorders

Clinical and therapeutic perspectives Minimal residual disease View of patient organizations

Early registration deadline: August 10, 2015. More info ehaweb.org

Integrated approach to demanding hematological diagnoses; from MDS to leukemias

EHA-SWG SCIENTIFIC MEETING REGISTERNOW!ehaweb.org

Avet-Loiseau H, FranceBeksac M, TurkeyBertoni F, ItalyBornhäuser M, GermanyBrand A, the NetherlandsBranford S, AustraliaBrune M, SwedenBullinger L, GermanyCamaschella C, ItalyCraddock C, United KingdomCross N, United KingdomDargaud Y, FranceEbert B, USAEichinger S, AustriaEikenboom J, the NetherlandsEinsele H, GermanyErnst T, GermanyForni G, ItalyGerming U, GermanyGiordano P, the NetherlandsGrønbæk K, DenmarkHarris N, USAHochhaus A, GermanyHokland P, Denmark

Inati A, LebanonIolascon A, ItalyJardin F, FranceJäger U, AustriaKarlsson S, SwedenKjeldsen-Kragh J, NorwayKröger N, GermanyKyrle P, AustriaLengfelder E, GermanyLubbert M, GermanyMacintyre L, FranceMeijers A, the NetherlandsMrozek K, USAMueller C, GermanyNagler A, IsraelOcio E, Spaino'Hare T, USAPanzer S, AustriaPanzer-Grumayer R, AustriaPapadaki T, GreecePatriarca F, ItalyPerrier A, SwitzerlandPeters C, AustriaPileri S, Italy

Piris MA, SpainRalfkiær E, DenmarkRawstron A, United KingdomRoberts I, United KingdomRosenquist R, SwedenSaid J, USASantoso S, GermanySchrappe M, GermanySomervaille T, United KingdomStanworth S, United KingdomStroncek D, USATrneny M, Czech RepublicVandekerkhove B, BelgiumVersteeg H, the NetherlandsVilk S, IsraelWu K, USAZucca E, Switzerland

European Hematology Association EHA Executive OfficeKoninginnegracht 12b2514 AA The HagueThe NetherlandsTel: +31 (0)70 3455 563 Fax: +31 (0)70 3923 663E-mail: info@ehaweb.org

Congress LogisticsMCI AmsterdamJan van Goyenkade 111075 HP AmsterdamThe NetherlandsTel: +31 (0)20 679 34 11 Fax: +31 (0)20 673 73 06E-mail: eha@mci-group.com

Hotel AccommodationMCI AmsterdamJan van Goyenkade 111075 HP AmsterdamThe NetherlandsTel: +31 (0)20 679 34 11 Fax: +31 (0)20 673 73 06E-mail: eha2015-hotels@mci-group.com

E D U C AT I O N B O O K R E V I E W E R SEHA would like to thank the following persons for their time and efforts reviewing the manuscripts for the Education Book ofthis Congress.

O R G A N I Z E R S

e h a w e b . o r g 23

Exclusive this year at the 20th Congress of EHA!

The book is also available for purchase €15,-

FRESH BLOODCelebrating 25 years of the European Hematology Association

Already a member? Use your history book voucher to collect your free copy of FRESH BLOOD at the EHA Booth!

Not a member yet?Join EHA and receive a free copy at the EHA Booth!

AWARDS

EHA Research FellowshipsClinical Research Fellowships

For clinicians with a PhD or equivalent research experience who wish to consolidate their research training or who are establishing their own independent research groups.Award: €80K/year for three years

Non-Clinical Junior Research FellowshipsFor non-medical scientists with 1 – 4 years of postdoctoral experience.Best application is awarded the José Carreras Non-Clinical Junior FellowshipAward: €50K/year for three years

Non-Clinical Advanced Research FellowshipsFor non-medical scientists with 4 years of postdoctoral experience.Award: €80K/year for three years

EHA EARLY CAREER OPPORTUNITIES

CALLS ARE NOW

OPEN!

27

Andolfo I, ItalyBahlo J, GermanyBalassa K, HungaryBeekman R, SpainBeguelin W, United StatesBill M, GermanyBödör C, HungaryCastagnetti F, ItalyCavalloni C, ItalyCecchetti C, ItalyChai-Adisaksopha C, ThailandCrivellaro S, ItalyDe Grandis M, FranceEllithy H, EgyptEscribà L, SpainFornari T, BrazilGabriel A, United KingdomGaidzik V, GermanyGkotzamanidou M, United StatesGlodkowska-Mrowka E, PolandGroarke E, IrelandGugliotta G, ItalyGuitart A, United KingdomGuo J, IrelandGuolo F, ItalyGuryanova O, United StatesHansen J, DenmarkHelman R, BrazilHoell J, GermanyHultcrantz M, SwedenJanse van Rensburg W, South AfricaJiménez A, SpainJóna Á, HungaryJónsdóttir G, IcelandKapralova K, Czech RepublicKarim S, United KingdomKerstjens M, the NetherlandsKon A, JapanKoniali L, United KingdomKroeze L, the NetherlandsKrupka C, Germany

Liberante F, United KingdomLiu C, TaiwanLjungström V, SwedenMagistroni V, ItalyMarneth A, the NetherlandsMartinez N, United KingdomMcGlauflin R, United StatesMcKerrell T, United KingdomMessina M, ItalyMikulasova A, Czech RepublicMilani P, ItalyMoulis G, FranceMuench V, GermanyMunneke M, the NetherlandsOellerich T, GermanyOkosun J, United KingdomPapayannidis C, ItalyPark J, United StatesPassaro D, United KingdomPawlyn C, United KingdomPetinati N, RussiaPsaila B, United StatesPugliese N, ItalyRahman K, IndiaRaponi S, ItalyRocci A, United KingdomRomano A, ItalyRoux C, FranceRusso R, ItalySanders M, the NetherlandsSasca D, GermanySchneider M, United KingdomSepulveda C, United KingdomShapira S, IsraelShivarov V, BulgariaSocoro Yuste N, FranceSun Y, ChinaSzabo A, the NetherlandsTakam Kamga P, ItalyTang B, ChinaTrinquand A, France

Valletta S, United KingdomVinchi F, GermanyVisentin A, ItalyVukovic M, United KingdomZaleska J, Poland

Travel Grant Supported By Giuseppe Bigi AssociationNucera S, Italy

T R AV E L G R A N T W I N N E R SFor this Congress 88 travel grants have been awarded to junior members of EHA, based on the mean score of their abstracts.Of these travel grants 7 have been reserved for abstract authors from countries with lower- and lower/middle incomeeconomies.

EHA congratulates the following persons with their travel grants:

JOSÉ CARRERAS LECTUREThe José Carreras Award was established by EHA inorder to honor leaders in hematological research and ispresented each year to an established and activeinvestigator who has made an important contribution tohematology. This honor has been bestowed oninternationally recognized specialists for their invaluablecontribution to the field of hematology.

EHA congratulates the winner of the 2015 José CarrerasLecture and Award, Professor Hugues de Thé (FR) forhis outstanding contributions to the understanding of thebiology of acute promyelocytic leukemia (APL), moreimportantly his work on the mechanisms of action ofarsenic trioxide in APL. During the Opening Ceremony,Professor de Thé will present the José Carreras HonoraryLecture. This lecture takes place on Friday, June 12 from13:30 – 14:15 in Room A2 + A3.

The previous winners are:2014 H Döhner, Germany2013 K Rajewsky Germany2012 J San Miguel, Spain2011 D Higgs, United Kingdom2010 B Falini, Italy2009 W Vainchenker, France2008 J Goldman, United Kingdom2007 R Bertina, the Netherlands2006 E Gluckman, France2005 H Waldmann, United Kingdom2004 V Diehl, Germany2003 C Verfaillie, Belgium2002 L Luzzatto, Italy2001 M Greaves, United Kingdom2000 D Collen, Belgium1999 C Rozman, Spain

JEAN BERNARD LIFETIME ACHIEVEMENT AWARDThe Jean Bernard Lifetime Achievement Award wasestablished in 2008 to honor outstanding physicians andscientists for their lifetime contribution to the advancement ofhematology. EHA is proud to award the 2015 Jean BernardLifetime Achievement Award to Professor Volker Diehl (DE). Volker Diehl was a pioneer in the field of Hodgkin Lymphomaand co-founder of the German Hodgkin Study Group (GHSG).

The award will be presented to Professor Diehl during PlenarySession I, which takes place on Saturday, June 13 from 13:00 – 14:15 in Room A2 + A3.

The previous winners of the award are:2014 F Stevenson, United Kingdom2013 T Barbui, Italy2012 L Degos, France2011 B Löwenberg, the Netherlands2010 E Montserrat, Spain2009 P Mannuccio Mannuci, Italy2008 D Hoelzer, Germany

28

FELLOWSHIP WINNERSThe call for applications are now open!EHA’s Career Development program promotes Europeanresearch in hematology and supports young basic, clinicaland translational researchers in pursuing their career goals byoffering a number of fellowship and training opportunities.Each fellowship has a specific target aimed at fulfilling theneed of a certain area in hematology or region. EHAFellowships are also open to EHA members from non-European countries.

The winners will be acknowledged during the OpeningCeremony on Friday, June 12.

EHA RESEARCH FELLOWSHIPSCLINICAL� B Gentner, Italy: John Goldman

� K Metzeler, Germany

NON CLINICAL JUNIOR� I Triviai, Germany: José Carreras

� G Simonetti, Italy

� E de Pater, the Netherlands

NON CLINICAL ADVANCED� S Altamura, Germany

� D Kent, United Kingdom

SHORT TERM VISITING AWARD� C Dufour, Argentina

EHA-JSH FELLOWSHIP EXCHANGE PROGRAM� N Yoshida, Japan

� A Balduini, Italy

EHA-ISTH FELLOWSHIP EXCHANGE PROGRAM� Winner to be announced

EHA-ASH TRANSLATIONAL RESEARCH TRAINING IN HEMATOLOGY (TRTH) PROGRAM 2015TRTH Trainees 2015:I Antony-Debre, USAP Bachireddy, USAL Couronné, FranceM de Witte, the NetherlandsA Fager, USAE Hadzijusufovic, AustriaG Horne, United KingdomM Jung, USAJ Jutzi, GermanyM Koupenova-Zamor, USAM Kwok, United KingdomP Maiso, SpainJ Micol, USAC Ott, USAC Riether, SwitzerlandA Roy, United KingdomM Smith, USAZ Tothova, USAM Wlodarski, GermanyYY Yeh, USA

e h a w e b . o r g 29

European Hematology Association

January 1, 2016Start abstract submissionand congress registration

March 1, 2016Deadline abstract submission

May 10, 2016Deadline early registration fee

KEY INFORMATION

Wednesday, Thursday, Friday, Saturday, SundayJune 10 June 11 June 12 June 13 June 14

Cloakroom(Entrance Hall) x 07:00-20:30 07:00-19:15 07:00-19:15 07:00-16:00CME Booth (Hall A) x 07:30-18:30 07:30-17:30 07:30-17:30 07:30-14:30EHA Booth(Hall A) x 07:30-18:30 07:30-17:30 07:30-17:30 07:30-14:30Congress Run Registratrion Desk(Entrance Hall) x x 09:00-17:00 x xExhibition (Hall B) x 09:30-16:30 09:30-16:30 09:00-16:30 09:00-13:00Poster Desk(Hall C) x x 09:30-19:00 09:30-19:00 09:30-11:00Press Center(Next to entrance Hall C) x 07:30-18:00 07:30-18:00 07:30-18:00 07:30-14:00Registration Area(Hall A) 13:30-17:30 07:00-18:30 07:00-17:30 07:30-17:30 07:30-16:00Speaker Service Center (Hall A) 13:30-17:30 07:00-18:30 07:00-17:30 07:30-17:30 07:30-13:00Vienna/Congress Information (Entrance Hall) 13:30-17:30 07:00-20:30 07:00-19:15 07:00-19:15 07:00-16:00

32

O P E N I N G H O U R SPlease find below all opening hours of the different areas and information desks.

C O N G R E S S I N F O R M AT I O NVENUEThe congress will take place at the Reed Messe Vienna;Messeplatz 1, 1020 Vienna, Austria.

REGISTRATION HOURSThe registration area in Messe Vienna will be open during thefollowing hours:Wednesday June 10 13:30-17:30Thursday June 11 07:00-18:30 Friday June 12 07:00-17:30 Saturday June 13 07:30-17:30 Sunday June 14 07:30-16:00

EXHIBITION The exhibition will be open on the following days and times:Thursday June 11 09:30-16:30 Friday June 12 09:30-16:30 Saturday June 13 09:00-16:30 Sunday June 14 09:00-13:00

EHA BOOTH The EHA Booth is located in Hall A. Please come and visit usto collect your EBAH Credit Points, get information onmembership, the EHA Learning Center and to find out whatmore EHA can do for you!

BADGESAll participants will receive a personal badge uponregistration. You are kindly requested to wear this badgewhen attending any scientific session or congress relatedevent. Only participants who are wearing their name badgewill be admitted to the meeting rooms, the exhibition area,satellite symposia and updates-in-hematology.

Name badges have been color-coded as follows:RED EHA members ORANGE EHA junior membersGREEN delegatesYELLOW junior delegatesBLUE exhibitorsPURPLE pressThe charge for replacement of lost badges will be €25.

SOCIAL MEDIAEHA is also active on various social media platforms. To getthe latest updates regularly, follow EHA on Facebook andTwitter at: Facebook: European Hematology AssociationTwitter: @EHA_Hematology

PRESS CENTERThe Press Center is located next to entrance Hall C. Pressinquiries prior to and after the annual congress should bedirected to EHA Executive Office +31 (0)70 3020 099.

The Press Center will be open on the following hours:Thursday, June 11 07:30 – 18:00Friday, June 12 07:30 – 18:00Saturday, June 13 07:30 – 18:00Sunday, June 14 07:30 – 14:00

CERTIFICATES OF ATTENDANCECertificates of attendance will be available in the RegistrationArea as of Friday, June 12 (from 12:00) until Sunday, June 14(until 16:00).

MESSAGE DESKAt the message desk participants can leave or collectmessages. Message alerts will be visible on the screensthroughout the congress center. The message desk is locatedin the Registration Area (see floor plan, back cover) and isopen during registration hours.

INTERNETWiFi is available in all areas. The network name is: EHA Also anumber of internet corners can be found on the Exhibition andin the back of Hall B, see the floor plan on the back cover.

CLOAKROOM AND LUGGAGEIn the cloakroom you can leave your belongings free ofcharge. The cloakroom is located in the Entrance Hall (seefloor plan, back cover) and will be open on the followinghours:Thursday, June 11 07:00 – 20:30Friday, June 12 07:00 – 19:15Saturday, June 13 07:00 – 19:15Sunday, June 14 07:00 – 16:00

LOST AND FOUNDItems that are found by Messe Vienna and EHA staff will bebrought to the Registration Services Desk (Registration area).Should you have lost any of your personal belongings, wekindly ask you to visit this desk to report it or to pick up items.

INSURANCEIn registering for the 20th Congress of EHA, participants agreethat neither the organizing committee nor the congressorganizers assume any liability whatsoever. Participants arerequested to make their own arrangements with respect tohealth and travel insurance.

e h a w e b . o r g 33

PRAYING ROOMPraying rooms are located in the entrance hall (see floor planon page 306).

LUNCH & REFRESHMENTSLunch is included in the registration fee from Friday untilSunday. Lunch tickets are attached to the badge sheet ofparticipants. These tickets are valid on Friday, June 12,Saturday, June 13 and Sunday, June 14. Lunch will beprovided in the Catering Area (located on the Exhibition inHall B). You can choose your own lunch items. On Sunday EHA would like to celebrate the anniversary withyou by offering you some Viennese treats and cake, you areinvited to attend this 20th Congress Anniversary Celebrationafter Plenary II, in front of Room A2+3.

EHA CONGRESS RUNThe congress run (5km) will take place on Saturday June 13,06:45 – 08:00. The start is at the Kaiserallee in Vienna. (Nextto the congress center Messe Vienna). You can register onlineor on-site on Friday June 12, 09:00 - 17:00. Join this healthystart of the day!

34

Service Name LocationAbstract/Education Book Books Desk Registration AreaCash withdrawal Cash dispenser Entrance HallCity and excursion information Vienna/Congress Information Desk Entrance HallCloakroom and luggage Cloakroom Entrance HallEmail and internet Wired Internet Corners Hall B Exhibition information Exhibitor desk Registration AreaFirst aid First Aid Office Entrance HallHotel Information Hotel Information Desk Registration AreaLost and found Registration Services Desk Registration AreaMeet-the-Expert ticket Meet-the-Expert Desk Registration AreaMessages Message Desk Registration AreaEHA Congress Run registration EHA Congress Run registration desk Entrance HallNetworking Event tickets Networking Event Desk Registration AreaPoster information Poster Desk Poster Area, Hall CRestaurant information Vienna/Congress Information Desk Entrance HallPresentation check-in Speaker Service Center Registration AreaWiFi Wireless Internet Throughout the venue

SERVICES PROVIDED DURING CONGRESS

CONGRESS MATERIALS ON THE EHA LEARNING CENTER The EHA Learning Center is the official learning platform ofEHA. The platform offers an extensive library with all EHA’seducational resources and activities. The educationalmaterials presented at the EHA Learning Center aim to servethe needs of the diverse hematological community: trainees,supervisors and established hematologists.

The following congress materials will be available on the EHALearning Center during or shortly after the congress:• Abstracts• Webcasts of various congress sessions • E-posters• Podcast interviews • Education Book• EHA TV Recordings

Visit the EHA Learning Center online atlearningcenter.ehaweb.org or come by the EHA Booth tofind out more about how to get access!

HARDCOPY ABSTRACT AND EDUCATION BOOKIf you have pre-registered for the hardcopy of an Abstractand/or Education Book, a voucher will be attached to yourbadge sheet. With this voucher you can pick up your book(s)at the Abstract / Education Book desk. If you would like tobuy a hard copy onsite, please go to the Book desk in theRegistration Area.

EHA TVThis year EHA will launch a digital television channel calledEHA TV. The online television channel will consist of aselection of semi-live reports and presentations recorded andbroadcast during the congress in Vienna. The stream is alsoavailable for everyone not attending the congress, and thisway should reach a big audience. You can view EHA TV fromthe mobile app or the website.

EHA NEWSAt the end of every congress day an EHA News bulletin willbe recorded in the EHA Theater in Hall A. The length of thebulletin is about 45 minutes to 1 hour and consists of the livediscussion of content of that congress day. In the studio ahost will discuss with 3 or 4 guests the topics of the day.

EHA THEATERThe EHA TV programs will be recorded in the EHA Theater, alive studio in Hall A. This EHA Theater will host a full program

of recorded talks, news bulletins and a series of meet-the-speaker sessions.

SPEAKER SERVICE CENTER Equipment to enable a final check of your PowerPointpresentation is available in the Speaker Service Center locatedin Registration Area in Hall A (see floor plan, back cover). The Speaker Service Center will be open on:Wednesday, June 10 13:30-17:30Thursday, June 11 07:00-18:30Friday, June 12 07:00-17:30Saturday, June 13 07:30-17:30Sunday, June 14 07:30-13:00

Only PowerPoint presentations will be accepted. To ensurethat the presentations are well prepared, we strongly adviseyou to bring your presentation AT LEAST 3 HOURS before thestart of your presentation to the Speaker Service Center. You can bring your presentation on a USB memory stick. Youmay bring your own laptop (exclusively for copying yourpresentation onto the network). The use of your own laptopduring your presentation is strictly prohibited.

EHA MOBILE APPA special mobile app has been developed for this congress inwhich you can find the entire program in detailed information.Use the app to find sessions of interest, create your ownprogram, find and read all the abstracts and locate themeeting rooms. This year you can also follow EHA TV fromthe mobile app, keeping you up-to-date on the congressthroughout the days. Download the app from the Apple Appstore or Google-Play, or use the QR Code on page 80

MEET-THE-EXPERT SESSIONS – €10 PER TICKETMeet-the-Expert sessions are held on Friday, June 12 andSaturday, June 13 from 14:30 – 15:30. In total 12 sessions willbe organized. The number of participants is limited to 50persons per session in order to guarantee the opportunity ofintensive interaction with leading experts in the field. Pre-registration for these sessions is necessary and tickets canbe purchased during registration hours at the Meet-the-Expert desk in the Registration Area. Meet-the-Expert ticketswill be sold on a “first come, first serve” basis and the priceper ticket is €10. For the Meet-the-Expert program see pages94 and 133.

WEBSITEUp-to-date information regarding the congress program,including all abstracts, is available at the congress section ofwww.ehaweb.org.

e h a w e b . o r g 35

S C I E N T I F I C I N F O R M AT I O N

POSTER WALK AND POSTER BROWSING TIME (NEW SETUP)The main goal of the poster session is to gain a maximumbenefit from the scientific work presented and to create alively interaction between poster authors, moderators (seniorexperts in the field) and interested congress participants. Thesetup of the Poster Session has been changed for the 20th

Congress of EHA. The Poster Session will consist of twoparts; the Poster Walk and Poster Browsing Time. This newsetup will guarantee sufficient time for all posters that havebeen selected for a presentation. In the first hour of thesession poster walks will be organized and during the PosterBrowsing Time the rest of the posters can be browsed on thee-poster screens available in the poster area.

Poster walks will be organized during the poster sessions onFriday, June 12 and Saturday, June 13 from 17:15 - 18:15.Poster authors and moderators are requested to be presentat the first poster in their poster session, at the beginning ofthe presentation time (17:15).

Poster browsing time will be organized after the poster walkon Friday, June 12 and Saturday, June 13 from 18:15 – 18:45.

POSTER AREA AND (E-)POSTER DESK Poster sessions will take place in the Poster Area (Hall C). The Poster Area and (E-)Poster Desk will be open on:Friday, June 12 09:30 – 19:00Saturday, June 13 09:30 – 19:00Sunday, June 14 09:30 – 11:00

FREE POSTER PRINTING SERVICEPoster presenters that have submitted their posters online(before May 30) to the poster printing service offered byCelgene, can collect their posters at the Poster Desk in thePoster Area (Hall C).

POSTER MOUNTING � Posters should be mounted during the indicated set-up

time (see below).� Posters should be mounted with double sided tape or

Velcro tape.� Assistance and material for mounting the posters will be

available from set-up time (see below), at the poster deskin the Poster Area.

POSTER VIEWING AND PRESENTATION� Posters will be on display in the Poster Area for two days

and will be open for viewing on Friday and Saturdayduring registration hours.

� Poster authors are requested to be present at their posterduring the entire presentation time (see below) to attendthe Poster walks. During these walks, an expert in thefield will discuss posters in the same poster session,together with interested congress participants.

REMOVING YOUR POSTER MATERIAL� Material should be removed after Poster Session II

(Saturday, June 13 as of 18:45).� If posters are not removed before 11:00 on Sunday,

June 14, they will be removed and disposed of.

DISCLOSURESAs part of the European Board for Accreditation in Hematology(EBAH) accreditation procedures, all speakers and chairs havebeen obliged to provide disclosures of relevant financialrelations. The disclosures of all invited speakers and chairs ofthe 20th Congress have been included in the disclosure indexon page 227. On the first slide of every presentation thedisclosure must be presented for at least 10 seconds.

PROGRAM CHANGESUp-to-date program changes will be indicated on themessage screens located throughout the congress center.

36

Poster Session I – Friday, June 12 Poster Mounting Friday, June 12, 09:30 - 12:00Viewing Friday, June 12, 09:30 - Saturday, June 13, 18:45Presentation during poster walk Friday, June 12, 17:15 - 18:15NEW: Poster Browsing Time Friday, June 12, 18:15 - 18:45Dismantling Saturday, June 13, 18:45 - Sunday, June 14, 11:00

Poster Session II – Saturday, June 13Poster Mounting Friday, June 12, 09:30 - 12:00Viewing Friday, June 12, 09:30 - Saturday, June 13, 18:45Presentation during poster walk Saturday, June 13, 17:15 - 18:15NEW: Poster Browsing Time Saturday, June 12, 18:15 - 18:45Dismantling Saturday, June 13, 18:45 - Sunday, June 14, 11:00

G E N E R A L I N F O R M AT I O NLANGUAGEThe official language during the congress is English andtherefore all presentations will be given in English.

CLIMATEThe average temperature is around 18-20 degrees. June isthe beginning of summer and from this month on Vienna seesmuch more sun and you can enjoy the warm weather. Makesure you protect yourself against the sun and keep hydrated.

ELECTRICITY SUPPLYAustria uses 220 volt alternating current. Plugs and socketsare European standard with two round pins.

BANKING SERVICEThe official currency in Vienna is the Euro (EUR). Foreigncurrencies can be exchanged at banks, which are usuallyopen from Monday to Friday from 08:30 to 15:30. ATM Cashdispensers (Bancomat) are located all over the city, inside thecongress center, at the airport and railway stations.

CURRENCY FOR CONGRESS RELATED PAYMENTSAll payments related to your congress registration should bemade in Euro (€).

VIENNA INFORMATION For practical information about the city please visit theVienna/Congress Information Desk. This desk is located inthe Entrance Hall of Messe Vienna and will be open duringthe following hours:Wednesday, June 10 13:30-17:30Thursday, June 11 07:00-20:30Friday, June 12 07:00-19:15Saturday, June 13 07:00-19:15Sunday, June 14 07:00-16:00

HOTEL INFORMATION DESK For hotel information and reservation you are welcome at theHotel Information Desk. This desk is located in theRegistration Area and will be open on:Wednesday June 10 13:30-17:30Thursday June 11 07:00-18:30 Friday June 12 07:00-17:30 Saturday June 13 07:30-17:30 Sunday June 14 07:30-16:00

DINING OUT IN VIENNA & TIPPINGRestaurants in Vienna are usually serving lunch from 11:30until 14:00. Dinner starts serving at 18:00 with busiest hoursbetween 19:00-21:00. Dinner bookings are recommended. Itis also recommended to leave a gratuity of 5%-10% of thebill if the service was satisfying. For more information aboutrestaurants, menus and bookings, please visitwww.mytable.com.

e h a w e b . o r g 37

P U B L I C T R A N S P O R T

38

e h a w e b . o r g 39

T R A N S P O R TAT I O N I N V I E N N ATHE EHA CONGRESS BADGE IS YOUR PUBLIC TRANSPORT TICKET!Public Transport is included in your registration. The backside of your congress badge is your public transport ticket.Your congress badge will be valid from Thursday June 11until Sunday June 14 and allows you unlimited travel throughVienna - day or night - using the bus, tram, metro and train –within zone 100. The City Airport Train (CAT) is not included.Vienna Airport is situated outside zone 100; a separate ticketshould be purchased for this travel. For more informationabout the public transportation in Vienna, please refer to thePublic Transport Map which is included in your congress bagor visit www.wienerlinien.at.

HOW TO REACH THE CONGRESS VENUE MESSE VIENNA

From the airport

By public transport from Vienna Airport to Messe Vienna:� CAT (City Airport Train) to Wien Mitte/Landstraße, take the

U4 line in direction Heiligenstadt, get out at Schottenringand take the U2 line in direction Seestadt.

� Schnellbahn S7 in direction Südbahnhof, get out atPraterstern and take the U2 line in direction Seestadt

� Bus (Vienna Airport Lines) to Morzinplatz, take the tram 1in direction Stefan-Fadinger-Platz, get out at Schottenringand take the U2 line in direction Seestadt

By TrainBy public transport from Vienna railway stations to MesseVienna:� Sud/Ostbahnhof (under construction), replacement:

Meidling/Philadelphiabrücke- Underground U6 in direction Floridsdorf toLängenfeldgasse, U4 line in direction Heiligenstadt toSchottenring, U2 line in direction Seestadt

- Schnellbahn to Praterstern, U2 line in directionSeestadt

� Westbahnhof- Underground U3 in direction Simmering toVolkstheater, U2 line in direction Seestadt

� Franz-Josefs-Bahnhof- Tram line 5- Tram line D- Tram line 33

� Bahnhof Praterstern- Underground U2 in direction Seestadt

By Public Transport � U2 Underground line Karlsplatz - Seestadt: Exit at station:

Messe-Prater� Bus line 11A Heiligenstadt - Seestadt: Exit at station

Krieau� Bus line 80B Kaiserebersdorf - Seestadt: Exit at station

Krieau

By TaxiTaxi ranks are right in front of the main entrance of MesseVienna. To call a taxi, please dial:+43 (0) 1 40 100+43 (0) 1 60 160

PROGRAM OVERVIEW

42

Hematology-in-FocusSessions

Updates-in-Hematology Updates-in-Hematology

08:00 �08:15 �08:30 �08:45 �09:00 �09:15 �09:30 �09:45 �10:00 �10:15 �10:30 �10:45 �11:00 �11:15 �11:30 �11:45 �12:00 �12:15 �12:30 �12:45 �

13:00 �

13:15 �13:30 �13:45 �14:00 �14:15 �14:30 �14:45 �15:00 �15:15 �15:30 �15:45 �16:00 �16:15 �16:30 �16:45 �17:00 �17:15 �17:30 �17:45 �18:00 �18:15 �18:30 �18:45 �19:00 �19:15 �19:30 �19:45 �20:00 �

SatelliteSymposia

EducationSessions

Opening Ceremony Fellowships & GrantsJosé Carreras Lecture

Plenary Session II

Business Meeting

Plenary Session I

Presidential Symposium (Best abstracts)

EducationSessions

MolecularHemopoiesisWorkshops

Poster Session I Poster Session II

Simultaneous Session

Jean Bernard Lifetime Achievement (13:00 - 13:15)

ScientificWorkingGroups

Basic Science-in-

Focus

ScientificWorking Groups

Basic Science-in-

Focus

EducationSessions

EducationSessions

Education Sessions

Education Sessions

AdvocacySession

AdvocacySession

ScientificWorkingGroups

Basic Science-in-

Focus

ScientificWorking Groups

Basic Science-in-

Focus

Scientific WorkingGroups

Basic Science-in-Focus

Scientific WorkingGroups

Basic Science-in-Focus

AdvocacySession

Scientific Working Groups

Late BreakingAbstracts

SatelliteSymposia

SatelliteSymposia

SatelliteSymposia

Updates-in-Hematology

THURSDAY, JUNE 11

FRIDAY, JUNE 12

SATURDAY, JUNE 13

SUNDAY, JUNE 14

ClinicalDebates

Meet-the-Experts

ESH & Rotating Joint

Symposium

Simultaneous Session Simultaneous Session

Simultaneous Session

Hematology-in-FocusSessions

Meet-the-Experts

ClinicalDebates

JSH & RotatingJoint

Symposium

EHA / ASHJoint

Symposium

14:30 - 15:30

11:30 - 12:45

08:00 - 09:15

11:30 - 12:45

13:15 - 14:1513:00 - 14:30

14:30 - 15:00

13:00 - 14:15

08:30 - 09:3008:00-09:30

09:45-11:1509:30-11:00

11:15-12:45

08:00-09:30

08:00-10:00

10:45-12:45

13:30-15:30

16:15-18:15

18:30 - 20:00

09:45-11:1508:00-11:00

08:00-09:30

10:15-11:15

09:45 - 10:45

08:30 - 09:30

09:45 - 10:4509:30 - 10:30

11:45-12:45

10:45 - 11:45

14:30 - 15:30

17:15 - 18:45 17:15 - 18:45

15:45 - 17:00 15:45 - 17:00

P R O G R A M - AT - A - G L A N C E

e h a w e b . o r g 43

OBJECTIVES EHA CONGRESSThe EHA Annual Congress provides a forum for presentingnew data from clinical trials and basic research and sharingideas for hematological innovation as well as disseminatingevidence-based knowledge of primary clinical relevance.

Hematologists and affiliated professionals attending the EHACongress will be able to:� Enhance their knowledge of evidence-based approaches

on diagnosis and treatment of hematologic diseases.� Access the latest results on clinical and translational

research in hematologic disorders.� Be updated on emerging innovative techniques,

diagnostic tools and risk-assessment strategies inhematology and its subspecialties.

� Communicate, collaborate and network withrepresentatives of a large international audience –medical professionals, national hematology societies,patient groups, medical industry and the media.

These general goals for the Congress will be furtherelaborated with learning goals for the presentations of theEducation Sessions.

On the following pages you find information about thecongress program, new sessions and program changes.

REVISED CONGRESS PROGRAMThe congress program has been completely redesigned andaims to bring you more basic science, while maintaining thestrong clinical focus of the EHA Congress. The new setupallows you to attend more Education Sessions, wherepreviously you could attend maximum four sessions you cannow attend six. We have introduced basic-science-in-focusas well laboratory-diagnosis-in-focus sessions, intended tocreate clearly marked sessions for those interested in basicscience and laboratory diagnosis. Another important changeis the integration of EHA Scientific Working Group sessionsinto the congress program, providing primetime slots for theresults and discussions from the EHA umbrella networks.

This year we are also highlighting the importantdevelopments in the field of personalized medicine in thecongress program with a special track dedicated to this area.This 10th track is indicated in light brown in the program at aglance.

NEW SESSIONSOn Saturday, June 13, a joint symposium with the TurkishSociety of Hematology and the Indian Society ofHaematology and Blood Transfusion will demonstrate thejuxtaposition between Europe and the respective countrieswhere it comes to generics and biosimilars. Both Turkey andIndia have an interesting environment with respect tolegislation and reimbursement policies for research andproduction of generics and biosimilars.

Also new this congress is a session on Friday, June 12,focusing on European Union funded projects which willhighlight the results and importance of two research consortiaoperating on an international level. The significance of suchprojects cannot be underestimated, especially in the light ofpromoting and facilitating European clinical research.

The centennial volume of Haematologica will be celebratedon Friday in a session dedicated to advances in basicresearch which have been recently published in the journal.The session is scheduled on Saturday, June 13.

A B O U T T H E C O N G R E S S P R O G R A M W H AT ’ S N E W T H I S Y E A R ?

44

H E M AT O L O G Y C U R R I C U L U M – Y O U R E U R O P E A N C V PA S S P O R T

C M E A C C R E D I TAT I O NParticipants of the 20th Congress of EHA are eligible toreceive Continuing Medical Education (CME) Credit Pointsfrom the European Board for Accreditation in Hematology(EBAH), previously known as the EHA-CME Unit. CME iswidely accepted as a means to encourage individualpractitioners to maintain and develop professional knowledgeand skills. This accreditation system has been implementedas a service to European hematologists in response to thisneed. It facilitates identification and registration of CMEactivities, which have been submitted to a peer-reviewprocess and respond to pre-established quality standards.Attendants of the 20th Congress of EHA are eligible to receiveone Credit Point for every hour of accredited activity.

CME Credit Points will be awarded for the scientific andeducational sessions including Plenary Sessions, EducationSessions, Meet-the-Experts, Clinical Debates, Hematology-in-Focus, Basic Science in Focus, Laboratory Diagnosis-in-Focus, Simultaneous Sessions, the workshops, EHAScientific Working Groups Meetings and the Joint Symposiawith ASH, ESH, JSH, ISHBT and TSH.

HOW TO CLAIM YOUR CREDIT POINTSIf you wish to register for credits on-site, we kindly invite youto visit the EBAH CME booth, where staff will be happy toassist you. A sufficient number of computers are madeavailable to register with the EBAH system and collect yourCredit Points. The EBAH system was previously known as theEHA-CME system, account details and passwords remain thesame.

STEPS TO CLAIM YOUR CREDIT POINTSStep 1: Visit the EBAH website: www.ebah.org Step 2: If you are already an account holder in this system, you

may log in.In case you do not have an account yet, you may createan account on this page. Then wait for an emailconfirming your system log-in credentials.

Step 3: In order to proceed to collect your credits, please fillin the subsequent online questionnaire regarding themeeting.

Step 4: Your EBAH CME Credit Point Certificate will beavailable in your account.

For further assistance or more information on CMEaccreditation we kindly invite you to visit the EBAH booth orcontact: info@eha-cme.org T +31 (0)70 302 00 99.

EHA employs the term “European Hematology Curriculum” todemonstrate that its program is intended to promoteharmonization of hematology education and training, as wellas professional mobility within the European community. Italso aims to improve the quality of patient care. TheCurriculum describes the skills and competences of aspecialist in hematology and should be considered as a set ofrecommendations.

The Curriculum framework is made available especially forjunior specialist in the “CV Passport”. The CV Passport is acomprehensive, detailed and itemized description of thespecialty of hematology, and includes consensusrecommendations on minimum levels of competence. The CVPassport is primarily aimed at trainees, enabling them to viewand exploit the European Hematology Curriculum. It focuseson hematology as a mono-specialty including clinical anddiagnostic aspects. It also defines the degree of competencein internal medicine that is required to be a hematologist, butdoes not focus on the details of this specialty.

Moreover, it should be used with reference to differences indisease incidences and patient care within Europe. In suchinstances, national adaptations may be appropriate. Finally,the CV Passport includes a section on general skills withrelevance to hematological practice.

The CV Passport is an open access online tool, to keep trackof your training progress in each area of the EuropeanHematology Curriculum. With an EHA Guest account youhave free access to the CV Passport. Please visit the websiteehaweb.org to create your account.

Interesting note: The European Hematology Curriculum wasdeveloped in order to harmonize hematology education inEurope, and is endorsed by 27 National HematologySocieties.

e h a w e b . o r g 45

1

2

3

4

5

6

7

8

9

10

B

T

C

The sections of the Hematology Curriculum form the basis forthe ‘tracks of hematology’ that make navigating the congressprogram a bit easier. Please find below an overview of thetracks and subdivisions that constitute the tracks:

Tracks in Hematology:

Clinical Hematology Benign

Clinical Hematology: Myeloid malignancies

Clinical Hematology: Lymphoid malignancies and plasma cell disordersClinical Hematology: Stem cell transplantationand special therapyLaboratory diagnosis

Thrombosis and hemostasis

Transfusion medicine

General skills

Pediatric Hematology

Personalized medicine

Biology

Translational

Clinical

H O W T O G E T T H E M O S T O U T O F Y O U R C O N G R E S S� Download the mobile app (search: EHA20)

� Become an EHA Member to stay updated andreceive a free copy of Fresh Blood - The storyof EHA and developments in Europeanhematology

� Link your CME number to get your free EBAH-CME points at the CME counter in Hall A

� Enjoy the Opening Ceremony (Friday, 13:00 – 14:15)

� Follow EHA TV and the daily EHA News (viathe mobile app and the EHA website) or cometo the EHA Theater in Hall A to watch the live-recording

� Join the EHA Run; a healthy start of yourSaturday (06:45 from the Kaiserallee)

� Visit the Exhibition in Hall B

� Network at the Poster Sessions, in the seatingareas and at the Networking Reception(Saturday, 19:30)

� Celebrate our 20th Congress with cake afterthe last Plenary Session (Sunday, 14:30)

� Use the EHA Learning Center to re-experience the congress online from thecomfort of your own home

46

P R O G R A M - O V E R V I E W - P E R - D AY

SatelliteSymposium

Novartis

UNDERSTANDING THE ROLEOF EPIGENETICS IN THEPATHOGENESIS AND

TREATMENT OF MULTIPLEMYELOMA

SatelliteSymposium

Novartis

OPTIMIZING PATIENTOUTCOMES IN CML

SatelliteSymposium

Celgene

TAKING CONTROL OFMYELOMA: CONTINUOUS

ADVANCEMENTS IN PATIENTCARE

SatelliteSymposium

Takeda

KEY ISSUES IN THE TREAT-MENT OF LYMPHOMA: THE

ROLE OF CD30 IN DIAGNOSISAND MANAGEMENT

SatelliteSymposium

Celgene

PERSPECTIVES ON THETREATMENT OF MANTLE CELLLYMPHOMA AND FOLLICULARLYMPHOMA IN 2015 AND

BEYOND

SatelliteSymposium

Novartis

PARADIGM SHIFT IN THEMANAGEMENT OF

INADEQUATELY CONTROLLEDPOLYCYTHEMIA VERA

SatelliteSymposium

Janssen

PRACTICAL MANAGEMENT OFMULTIPLE MYELOMA IN ACHANGING TREATMENT

LANDSCAPE

SatelliteSymposium

Bristol-Myers Squibb

THE CML JOURNEY: LONG-TERM SURVIVAL

NECESSITATES PATIENTCENTRICITY

SatelliteSymposium

Celgene

EXPERT GUIDANCE INMYELOID MALIGNANCIES:DISCUSSING WHAT IS

IMPORTANT

SatelliteSymposium

Janssen

INTEGRATING NOVELTHERAPIES IN TO THE

PRACTICAL MANAGEMENT OFPATIENTS WITH CLL AND

MCL: INTERACTIVE PATIENTCASE STUDIES

SatelliteSymposium

Bristol-Myers Squibb

IMMUNO-ONCOLOGY: A NEWERA IN HEMATOLOGY

TREATMENT? EMERGINGRESEARCH IN LYMPHOMA

AND MYELOMA

SatelliteSymposium

Amgen

CHARTING NEW DEPTHS INTHE TREATMENT OF MULTIPLE

MYELOMA

SatelliteSymposium

Medscape Education

DEVELOPING STRATEGIESTARGETING CD20 IN NHL ANDCLL: CURRENT AND FUTURE

SatelliteSymposiumInvivoscribe

NGS-BASED CLINICALASSESSMENT OF B- AND T- CELL CLONALITY, MRDDETECTION, AND AML

STRATIFICATION

SatelliteSymposium

Ariad

WHEN IS PONATINIB ASUITABLE TREATMENT

OPTION FOR PATIENTS WITHCP-CML AND HOW CAN WEOPTIMIZE BENEFIT / RISK?

SatelliteSymposiumprIME Oncology

RELAPSED/REFRACTORYMULTIPLE MYELOMA:

EMBRACING THE PERSON INPERSONALIZED CARE

08:00

10:00

10:45

12:45

13:30

15:30

16:15

18:15

Room A2+3 Room A7 Room C1 Room C2 Room A8

P. 61

P. 64 P. 65 P. 65 P. 66

P. 68 P. 69 P. 69 P. 70

P. 72 P. 73P. 72 P. 73

P. 61 P. 62 P. 62

18:30

20:00

SatelliteSymposium

Gilead

THE CHANGING LANDSCAPE INCLL AND FOLLICULAR

LYMPHOMA: HOW DO NEWTARGETED THERAPIES IMPACT

PATIENTS' LIVES?

SatelliteSymposiumViforpharma

BURDEN, DIAGNOSIS ANDTREATMENT OF IRON

DEFICIENCY

Updates-in-HematologyGilead

Can we further improve CLL and FL patients’ lives?Recent advances and case

studies

e h a w e b . o r g 47

T H U R S D AY , J U N E 1 1

SatelliteSymposium

Novartis

EXTENDING EXPERIENCE INTHE MANAGEMENT OF ITP:WHAT HAS CHANGED OVER

THE LAST DECADE?

SatelliteSymposiumGenzyme

THE SHERLOCK HOLMESAPPROACH TO DIAGNOSIS

AND TREATMENT,THROMBOCYTOPENIA INRARE HEMATOLOGICAL

DISEASES

SatelliteSymposium

Amgen

APPLYING T-CELLENGAGEMENT STRATEGIES TO

THE TREATMENT OF ALL:EXAMINING THE EMERGING

DATA

SatelliteSymposium

Abbvie

HIGH RISK AND HIGHEREXPECTATIONS: WHAT DOESTHE FUTURE HOLD FOR

PATIENTS WITH P53 PATHWAY-DEFICIENT CLL?

SatelliteSymposiumprIME Oncology

BIOSIMILAR MONOCLONALANTIBODIES IN HEMATOLOGICMALIGNANCIES: WHAT YOU

NEED TO KNOW

Room Lehar 1+2 Room Lehar 3+4

SatelliteSymposium

Teleflex

THE BLOOD/BONE BIOPSY:PATIENT, PROVIDER,PROCEDURE, PAIN &PATHOLOGY PROCESS

SatelliteSymposium

Novartis

MORE EVIDENCE, MOREOPTIONS: FIRST-LINETREATMENT OF CLL

SatelliteSymposium

Takeda

SHIFTING PARADIGMS INMULTIPLE MYELOMA: FUTURE

INSIGHTS TO PRACTICE

SatelliteSymposium

Teva

CONTEMPORARYTHERAPEUTIC STRATEGIES IN

B-CELL LYMPHOMAS

SatelliteSymposium

Alexion

THROMBOSIS INHEMATOLOGICAL DISORDERS:TAILORED MANAGEMENT

APPROACHES

Updates-in-HematologyNovartis Oncology

Molecular monitoring in CML – from the bench

to the bedside

18:30

20:00

Room Strauss 1 Room Strauss 2 Room Strauss 3 08:00

10:00

10:45

12:45

13:30

15:30

16:15

18:15

P. 63 P. 63 P. 64

P. 67 P. 67 P. 68

P. 70 P. 71 P. 71

P. 74 P. 74 P. 75

P. 76 P. 77

48

Room A2+308:00

08:30

09:30

09:45

10:45

11:15

11:30

12:45

13:00

13:15

13:30

14:15

14:30

15:30

15:45

17:00

17:15

18:45

Opening Ceremony

Fellowships &Grants

Educationsession

Multiple myeloma

B T C

Room A7

SWG SessionERIC

B T

Room C1

Educationsession

Peripheral T-celllymphoma

T C

Room C2

MolecularHemopoiesis

Workshop

Room A8

Educationsession

Chronic myeloidleukemia

B T C

Room Lehar 1+2

EducationsessionStem cell

transplantation:Predicting and

preventing relapse

Room Lehar 3+4Room Strauss 1

SWG SessionMCL

Educationsession

Hemoglobinopa-thies preventionand therapy froma global healthpoint of view

B T C

EducationsessionMyelo-

proliferative neoplasms

B T C

SWGSessionLymphomas

B T C

Educationsession

Peripheral T-celllymphoma

T C

SimultaneousSessionMultiple

myeloma: ClinicalStudies 1

SimultaneousSession

Treatment andoutcome in non-Hodgkin lymphoma

SimultaneousSession

ALL Clinical Trials

SimultaneousSession

Molecular Patho-genesis in AML

SimultaneousSession

CLL - Biology: Interacting

determinants ofCLL ontogeny and

evolution

SimultaneousSessionStem Cell

Transplantation -Clinical 1

SimultaneousSession

Biology in MDS

SimultaneousSession

Red cells: Novelclinical aspects

EducationsessionStem cell

transplantation

T C

C

B T

EducationsessionAcute

lymphoblastic leukemia

T C

Educationsession

Hemoglobinopa-thies preventionand therapy froma global healthpoint of view

B T C

T C

Clinical DebateWill novel

drugs displaceautologous

transplantation inmyeloma ?

C

Hematology-in-Focus

At the crossroadsof autoimmunityand lymphoma

B T C

Hematology-in-Focus

Can clinical trialdesign keep upwith the pace ofdrug develop-

ment?

T C

Clinical DebateLongterm anticoa-gulation in patientswith antiphospholi-pid antibodies anda single throm-boembolic event

C

Hematology-in-Focus

Specific issues inhemoglobinopa-

thies

B T C

EU FundedProjects in

HematologyDissemination of

results

EHA - JSH JointSymposium

Multiple myeloma

Updates-in-Hematology

Celgene:Practical insightson the diagnosisand initial ma-

nagement of AML

B C

B T C

PresidentialSymposium Best Abstracts

POSTER SESSION I - Hall C

José Carreras Lecture

P.84

Early Career Hematologists Early Career Scientists

B

TB

B T CT C

P R O G R A M - O V E R V I E W - P E R - D AY

C C C B T B T

B T C

P. 81 P. 81

P. 85

P. 85

P. 81

P. 89

P. 82 P. 83 P. 83

P. 82 P. 85 P. 86 P. 86

P.88

P. 93

P. 88 P. 89 P. 90 P. 90 P. 91

P. 93P. 93

P. 95

P. 96

P. 93 P. 93 P. 93 P. 93 P. 94

P. 91

e h a w e b . o r g 49

08:00

08:30

09:30

09:45

10:45

11:15

11:30

12:45

13:00

13:15

13:30

14:15

14:30

15:30

15:45

17:00

17:15

18:45

Updates-in-Hematology

Pfizer:Evolution of treat-ments in acuteand chronic leukemia

Early CareerSession

Women's careersin hematology

Hematology-in-FocusJuvenile

myelomonocyticleukemia

B T C

Meet-the-Expert

New platelets antibody tests:New techniquesand clinical indication

T C

Meet-the-Expert

How to managered cell transfusionin patients withmultiple erythro-cyte antibodies

C

Meet-the-Expert

Chemotherapy orbiological agentsfor treating CLL

C

Meet-the-ExpertHodgkin lymphoma

C

Meet-the-Expert

Allogeneic SCT inmyelofibrosis

C

Meet-the-Expert

Age-related EBV-associatedlymphoprolifera-tive disorders

B T C

Room Strauss 2

EducationsessionPediatric

hematology

B T C

EducationsessionPediatric

hematology

B T C

Basic Sciencein Focus

Novel players inactivation of coagulation

B T

Basic Sciencein Focus

Animal models inhemostasis

B T

SWG SessionThrombocytope-nias and plateletfunction disorders

Basic Sciencein Focus

New concepts inpathophysiology of

red cells

B T

SWG SessionQuality of life and

symptoms

SWG SessionBleeding andthrombosis in

onco-hematology

B T C

C C

Basic Sciencein Focus

The heme and ironconnection

B T

Room Strauss 3 Room Stolz 1 Room Stolz 2 Room Schubert 1

Room Schubert 1 Room Schubert 2 Room Schubert 3 Room Schubert 4 Room Schubert 5

Room Schubert 2 Room Schubert 3

Early Career Hematologists Early Career Scientists

SimultaneousSession

Thrombosis andvascular biology

SimultaneousSession

Quality of life andhealth economics

Room Schubert 4

Room Schubert 6

F R I D AY , J U N E 1 2

1

2

3

Clinical Hematology: Benign

Clinical Hematology: Myeloid malignancies

Clinical Hematology: Lymphoid malignancies and plasma cell disordersClinical Hematology: Stem cell transplantation and special therapy

Laboratory diagnosis

TRACKS SUBDIVISIONS

4

5

6

7

8

9

10

Biology

Translational aspects

Clinical

Thrombosis and hemostasis

Transfusion medicine

General skills

Pediatrics

Personalized medicine

BTC

C C

P. 84 P. 84 P. 84 P. 84

P. 86

P. 87 P. 87

P. 92 P. 92

P. 87 P. 87

P. 94 P. 94 P. 94 P. 94 P. 94 P. 94 P. 94 P. 94

P. 97

50

P R O G R A M - O V E R V I E W - P E R - D AY

Room A2+308:00

08:30

09:30

09:45

10:15

10:45

11:15

11:30

12:45

13:00

13:15

14:15

14:30

15:30

15:45

17:00

17:15

18:45

Jean Bernard Lifetime

AchievementAward

EducationsessionPrimary cutaneous lymphoma

B T C

Room A7

SWG SessionMyelodysplasticsyndromes

Room C1

EducationsessionAcute

lymphoblastic leukemia

TC

Room C2

SWG SessionAcute myeloid leukemia

Room A8

Educationsession

Chronic myeloidleukemia

B T C B T CB C

Room Lehar 1+2

EducationsessionStem cell

transplantation

Room Lehar 3+4Room Strauss 1

EducationsessionThrombosis Basic Science

in FocusiPS Cells

B T

Educationsession

Multiple myeloma

B T C

SWGSession

European WorkingGroup for AdultALL (EWALL)

B T C

EducationsessionChronic

lymphocytic leukemia

B T C

Educationsession

Myelo proliferativeneoplasms

SWG SessionChronic myeloid

leukemia

B T C

SimultaneousSessionMultiple

myeloma: ClinicalStudies 2

SimultaneousSession

CLL: Novel agents

SimultaneousSession

Translational Studies in ALL

SimultaneousSessionStem Cell

Transplantation -Clinical 2

SimultaneousSession

MPN: Prognosisand treatment

SimultaneousSession

Molecular Markersin AML

SimultaneousSession

Oncogenic mecha-nisms and noveltargets in non-Hodgkin's lymphoma

Educationsession

Stem cell trans-plantation:

Predicting and preventing relapse

T C

T C

B T C

C

Educationsession

Bleeding disorders

T C

Educationsession

Red cell disease:New therapies forhemoglobinopa-

thies

B T C

Clinical DebateProphilactic ver-sus therapeuticplatelets transfu-sion in leukemiaand aplastic anemia

C

Clinical DebateTo stop or not to

stop TKI in molecular remis-sion of CML

T C

Early CareerSessionFunctional genomics

B T

Hematology-in-Focus

Stem cells andDNA repair

B T

Hematology-in-Focus

B-cell physiology

B T

Hematology-in-Focus

Management ofbleeding

C

Hematology-in-FocusOncolytic

virotherapy in lymphoid cancer

EHA - ISHBT &TSH Joint

SymposiumImproving accessto medicines: Generics and biosimilars

Updates-in-HematologyNovartis Sandoz:Why biosimilarsmatter: an inno-vative solution toimprove patient

access

B T

B T C

SimultaneousSession

MM - Biology

POSTER SESSION I - Hall C

SimultaneousSession

Optimization andinnovation in trea-ting aggressivelymphomas

SimultaneousSession

MDS - Clinical

SimultaneousSession

AML outcome andclinical trials

SimultaneousSession

CML: Clinical trials

SimultaneousSession

Biological pathwayderegulation in BCell Precursor ALL

SimultaneousSession Stem Cell

Transplantation:Experimental

PlenarySession 1

B

T CB

T CB

B T CT C

C

1

2

3

Clinical Hematology: Benign

Clinical Hematology: Myeloid malignancies

Clinical Hematology: Lymphoid malignancies and plasma cell disordersClinical Hematology: Stem cell transplantation and special therapy

Laboratory diagnosis

TRACKS SUBDIVISIONS

4

5

6

7

8

9

10

Biology

Translational aspects

Clinical

Thrombosis and hemostasis

Transfusion medicine

General skills

Pediatrics

Personalized medicine

BTC

C C

C

B T C

T C C C

T C

B T B T

Early Career Hematologists Early Career Scientists

P. 119 P. 119 P. 119 P. 120 P. 120 P. 120 P. 120

P. 126 P. 127 P. 127 P. 128 P. 128 P. 129 P. 129

P. 121

P. 131

P. 131

P. 131 P. 131 P. 131 P. 131 P. 131 P. 131 P. 131

P. 139

P. 133 P. 134 P. 134 P. 135 P. 135 P. 136 P. 136

P. 122

P. 123

P. 123 P. 123

P. 124

P. 124 P. 124 P. 125

e h a w e b . o r g 51

S AT U R D AY , J U N E 1 3

08:00

08:30

09:30

09:45

10:15

10:45

11:15

11:30

12:45

13:00

13:15

14:15

14:30

15:30

15:45

17:00

17:15

18:45

Updates-in-Hematology

Basilea:Management ofinvasive fungal in-fections: currentstatus and recentdevelopments

EHA - ESHJoint

SymposiumWhat is the right

treatmentfor me?

C

HaematologicaCelebration

Session

EHA Advocacysession Hematology Awareness:

Research Road-map/Cost of Blood

Disorders

C

Meet-the-Expert

Thrombotic-thrombocytopenic

purpura

C

Meet-the-ExpertMyeloma

emergencies

C

Meet-the-Expert

Diagnosis and treatment of mastcell disorders

C

Meet-the-Expert

Isolation of stemcells

Meet-the-Expert

Oncogenomics forclinicians

C

Meet-the-Expert

Aplastic anemiaon CSA ATGAM Eltrombopag

B TB T T C

SimultaneousSession

Platelet and bleeding disorders

SimultaneousSession

Iron clinical and biology

Room Strauss 2

Room Strauss 2

Patient Advocacy session Collaborating with patients for successful hematology

research and for assessmentof optimal benefits and risks

Patient Advocacy Session Collaborating with patients for successful hematology

research and for assessmentof optimal benefits and risks

EHA - ASH JointSymposium

Antimicrobial Resistance (AMR)

Laboratory Diagnosis in Focus

Hematological malignancies inspecific genetic or immunolo-

gical background

Laboratory Diagnosis in Focus

ISO-15189, standardization,and accreditation in laboratory

hematology diagnostics

Basic Science in FocusMarginal zone

B-cells in health and disease

B T

Basic Science in FocusRUNX1 and Leukemia

SWG SessionGranulocyte and monocyte

disorders

Education sessionTransfusion medicine: Focus on granulocytes

B T C

Basic Science in Focus

The role of niche in MDS: Preclinical models

SWG SessionAging and hematology

Room Strauss 3

Room Strauss 3

Room Stolz 1 Room Stolz 2 Room Schubert 1

Room Schubert 1 Room Schubert 2

Room Stolz 1 Room Stolz 2

Room Schubert 3 Room Schubert 4 Room Schubert 5

TB

CTB

Simultaneous SessionNovel actors in chronic myeloid

leukemia biology

Simultaneous SessionGene Therapy,

Cellular Immunotherapy and

vaccination

Room Schubert 6

C B T

B T

C

C

B T

B T

C

C

C

C

B T

C

B T

B TB C

Early Career Hematologists Early Career Scientists

P. 121 P. 121 P. 121 P. 122

P. 130 P. 130 P. 130

P. 122

P. 125

P. 125 P. 125 P. 126 P. 126

P. 132

P. 140

P. 137P. 137 P. 138

P. 132

P. 133 P. 133

P. 133 P. 133 P. 133 P. 133

52

P R O G R A M - O V E R V I E W - P E R - D AY

Room A2+308:00

09:15

09:30

10:30

10:45

11:00

11:15

11:30

11:45

12:45

13:00

14:30

15:00

Educationsession

Chronic lympho-cytic leukemia

B T C

Room A7

SWG SessionMyeloproliferative

neoplasms

Room C1

Educationsession

Myelodysplasticsyndromes

T

Room C2 Room A8

Educationsession

Diffuse large B-cell lymphoma

B T C

Educationsession

Acute myeloid leukemia

B T CB C

TB C

Room Lehar 1+2

SWG SessionStem cells

Late BreakingAbstracts 2

Room Lehar 3+4

Educationsession

Bleeding disorders

Educationsession

Primary cutane-ous lymphoma

B T C

SWGSession

Multiple myeloma

B T C

T C

Educationsession

Myelodysplasticsyndromes

B T C

Educationsession

Diffuse large B-celllymphoma

EducationSession

Acute myeloid leukemia

B T C

SWG Session

ESLHO/EuroFlow

T C

B T C

EducationsessionThrombosis

T C

SimultaneousSession Multiple

myeloma: ClinicalStudies 2

SimultaneousSession

CLL: Refining outcomes

SimultaneousSession

AML: Molecularprofile and targeting

SimultaneousSession Stem Cell

Transplantation:Clinical 3

SimultaneousSession

Progress in Hodgkinlymphoma therapy:Incorporation ofnovel agents andreduction of side

effects

B

B

B

T C

T

Business Meeting

Plenary Session 2

B T C

1

2

3

Clinical Hematology: Benign

Clinical Hematology: Myeloid malignancies

Clinical Hematology: Lymphoid malignancies and plasma cell disordersClinical Hematology: Stem cell transplantation and special therapy

Laboratory diagnosis

TRACKS SUBDIVISIONS

4

5

6

7

8

9

10

Biology

Translational aspects

Clinical

Thrombosis and hemostasis

Transfusion medicine

General skills

Pediatrics

Personalized medicine

BTC

C C T C T C C

Early Career Hematologists Early Career Scientists

P. 161 P. 161 P. 162 P. 162 P. 163

P. 169

P. 173

P. 170 P. 170 P. 171 P. 171

P. 169

P. 172

P. 165

P. 166

P. 169

P. 166 P. 166 P. 167

P. 167

P. 167

Simultaneous Session CML: Molecular-cytogenetic

diagnostics

Simultaneous Session Novel insights into the mechanisms involved

in MPNs

Simultaneous Session Towards targeted therapy in ALL

Simultaneous Session Biology and Clinics of Bonemarrow failure syndromes

and PNH

e h a w e b . o r g 53

S U N D AY , J U N E 1 4

Late Breaking Abstracts 1

Room Strauss 1

Basic Science in FocusConsequences of splicing

abnor-malities in hematopoiesis

Basic Science in FocusMolecular analysis

of IG genes

Laboratory Diagnosis-in-Focus

Clonogenic cells in hemato-on-cology: Relevance for diagnosis?

Basic Science in FocusGeneration and expansion of

HSC

SWG SessionRed cell and iron

Room Strauss 2

SWG SessionLeukemia diagnosis: morpho-logy and flow cytometry:

Unusual diagnoses in oncohe-matology, integration of

morphology and flow cytometry

Education sessionRed cell disease: New therapies forhemoglobino pathies

Basic Science in FocusOpposite roles of Notch

signalling

Room Strauss 3 Room Stolz 1 Room Stolz 2

Education SessionTransfusion

medicine: Focus on granulocytes

Basic Science in FocusNon-coding RNAs

B T C B T CB T

B T C

B T CB T C

B T B TC T C

B T C

B C

C

B TB T

C

08:00

09:15

09:30

10:30

10:45

11:00

11:15

11:30

11:45

12:45

13:00

14:30

15:00

Early Career Hematologists Early Career Scientists

P. 163 P. 164 P. 164 P. 165

P. 168 P. 168 P. 168

P. 168

P. 169

P. 172 P. 172 P. 172 P. 173 P. 173

EHA’s advocacy track brings together several interestingpatient and policy related issues.

Two sessions are organized by patient advocates. The firstPatient Advocacy Session concerns collaborating withpatients for successful hematology research and forassessment of optimal benefits and risks. In an era of growingdemand and emphasis on both quality and sustainability ofhealthcare, it is critical to involve patients in the R&D process,as it can accelerate research and make it more effective.

The second Patient Advocacy Session is about partnershipand evidence; key elements to improving access totreatment. This session will explore today's challenges, issuesand the opportunities of the future, and will present theperspective of a hematologist on access, as well as two casestudies from patient advocacy groups who have built newcollaborative approaches between patients, clinical expertsand policy makers to improving access to medicines.

The EHA-ASH Joint Symposium touches upon the issue ofAntimicrobial resistance (AMR). The profligate way we useantibiotics is creating bacteria resistant to all knownmedicine. Without reform, diseases that are now trivial will belethal in 20 years, and routine operations will become toorisky. This problem should be ranked alongside terrorism andclimate change on the list of critical risks to the EU.

The EHA-ESH Joint Symposium is an interactive session forhematologists and patients about what is the right treatmentfor me? Incorporation of genetic information into stratifieddecision making may enable the clinician to advise the patienton the need for further therapy based on the risk ofrecurrence or point the way to the choice of specific agentslikely to have selective activity against the underlying disease.

Lastly, the EHA Advocacy Session is about hematologyawareness. EHA advocates the interests of the medicaldiscipline of hematology and its practitioners in Europe. Toimprove its efforts, EHA developed a hematology awarenesscampaign and advocacy strategy. Policy makers andpoliticians need to be made aware of the discipline ofhematology and the policy issues that affect its researchersand clinicians. In the light of the Hematology Awarenesscampaign (started in 2014), this session will launch theoutcome of two important projects: The Research Roadmapfor Hematology in Europe, and the study into the Cost of

Blood Disorders. Together, these projects will support thecause of hematology with important evidence as to theeconomic burden of blood disorders affecting the EuropeanUnion and a European consensus paper on future researchneeds. A panel discussion with those involved should bring alively end to the Advocacy Track.

See you Saturday!

54

V I S I T E H A’ S A D V O C A C Y T R A C K !

e h a w e b . o r g 55

OPPORTUNITIES AND BENEFITS FOR EARLY-CAREERSCIENTISTS/HEMATOLOGISTSAs a young hematologist, it’s important to create yournetwork and to stay up-to-date in order to enrich yourprofessional life. EHA wants to assist you in reaching thesegoals and help you by creating a complete overview ofopportunities and benefits. Our goal is to create a programthat reaches beyond any singular event or activity andpresent these to you by earmarking them clearly as an ‘EarlyCareer Opportunity’. These opportunities include the specialEarly Career Sessions and networking events organized at thecongress as well as the Career Development Program andEHA Membership.

AT THE CONGRESSThe Early Career Track is launched with the organization oftwo Early Career Sessions, the program indicator ‘graduationcap’ and the Early Career Reception. Check the programbook for the cap-icon and discover in detail what EHA isoffering you. Here’s a quick overview;- Visit the EHA Booth to learn more about EHA’s CareerDevelopment Program.

- Utilize the learning goals in the final program now includedfor all presentations of the Education Sessions.

- Come to the Early Career Club Reception on Thursday,June 11, 18:00.

- Attend the Early Career Sessions on Friday and Saturday.- Don’t miss the EHA Networking Event in the famousViennese city hall on Saturday, June 13, 19:30.

INSIDER TIPS ON NAVIGATING THE CONGRESS PROGRAMThe schedule of the 20th Congress of EHA is againchallenging – and: full of opportunities. Finding the rightsessions to attend to get the maximum of knowledge, newconnections and experience out of the four days packed withinformation requires good advance planning and is also verydependent on your career stage and basic orientation. Thus,an early career hematologist in the first two years of clinicaltraining will have different needs than a clinical trainee in thefinal years before his or her specialization. Both of them willagain be very different from a basic scientist working inhematology.

The sessions in the program marked with a graduation capwill give you a first idea whether something may have specialrelevance for early career hematologists, but there might stillbe different approaches in the use of these icons.

HEMATOLOGISTSStarting with the example of a hematologist in the first yearsof training (perhaps this being your very first EHA), it might bea good idea to use this meeting to get an update on the majorhematologic diseases and be up-to-date with the currenttreatment strategies and outcomes of recent clinical trials.However, you can additionally use it as a chance to find yourpersonal niche or focus of interest – picking one disease (oreven disease aspect – eg, FLT3-mutated AML) and follow thistopic throughout the conference. In this way, you can startbuilding up your career to more than “just basic” – and evenmore importantly, you can use it to get in contact with peoplewho are already established in this field. Nobody is a betterteacher than an enthusiastic researcher talking about his lifetime work.

Very practical – starting your conference every morning withthe education sessions (with focus on the absolute “must-knows” like AML or Multiple Myeloma), then choosing oraland poster presentations to attend for your focused topic ofinterest, spiked in with the “must-see” PresidentialSymposium and Plenary Sessions will give you a solidstructure for the meeting. Most importantly, use all the waysto connect with other early career hematologists and alsopeople more advanced in their career- the EHA NetworkingReception, the Early Career Sessions and interactions withmembers of the Early Career Advisory Group (ECAG). Onlythis interaction will then ultimately lead to a different “EHAexperience” in the future – which is to look forward to meetand re-connect with your collaborators from all over Europeand the world.

Being more advanced in your career, the morning EducationSessions will still be a great opportunity to ensure to beinformed about the newest trends in the diseases youfrequently treat. In addition, they are also a good reminder fordiseases you see only rarely in your daily routine. Thus,picking a “common foe” for the start of the day, and then usethe second Education Session round for an update onbleeding disorders or new therapies for hemoglobinopathiesmight be a good way to ensure being informed about bestclinical practice – and also a nice way to be up to date forfuture board exams.

E A R LY C A R E E R T R A C K

As the research in hematology advances so fast and isalready a part of the daily clinical practice, using the “BasicScience in Focus” sessions (especially: “LaboratoryDiagnosis in Focus sessions” on Saturday/Sunday) and theSWG sessions is probably the best way to know where thefuture of hematology will be.Besides the “regular program”, the Annual Congress is also avery good opportunity to learn about the different fundingopportunities or exchange programs. The EHA booth andother information corners will provide a good way to not missout on anything.

BASIC RESEARCHERSAs a basic researcher, in addition to exchange research withother people working in your field, the goal might be tounderstand more about the specific disease you are studyingfrom a clinical perspective – and also get basic insights intoone or two additional diseases with the idea to possiblybroaden the research approach. Of course the main focushere will be the Basic Science in Focus and SWG sessions,flanked by the oral and poster presentations in your area. Butusing the Education Sessions as a way to increase the clinicalbackground will also be an important factor.

Most important for everybody is: get involved! EHA is whatyou want it to be – there are plenty of opportunities to discussyour ideas and to network. Also, don’t hesitate to approachmembers of the ECAG at any time during the congress.Please check the EHA booth for times to meet with themembers. We are a small field, but we are moving and we areconnected!

CAREER DEVELOPMENT PROGRAMSEHA also offers a range of career development programs andfellowships aiming and cooperating with different fields ofhematology and various parts of the world. Each fellowshiphas its own target group and set of eligibility criteria andsubmission, come to the EHA Booth and speak to ourdedicated staff or visit the Career section at ehaweb.org toget more information.

- EHA Clinical Research Fellowships Award 80K per year for a three-year period. For clinicianswith a PhD or equivalent research experience who wish toconsolidate their research training or who are establishingtheir own independent research groups. Online applicationis open!

- EHA Non-Clinical Junior Research FellowshipsAward 50K per year for a three-year period. For non-medical scientists with 1 – 4 years of postdoctoralexperience. Online application is open!

- EHA Non-Clinical Advanced Research FellowshipsAward 80K per year for a three year period. For non-medical scientists with ≥ 4 years of postdoctoralexperience. Online application is open!

- EHA-ASH Translational Research Training inHematology (TRTH)TRTH provides junior researchers with a unique, year-longtraining and mentoring experience focused on helpingearly-career hematological scientists build successfulcareers in hematologic translational research. Twenty early-career scientists are selected each year to participate inthis rigorous training program. TRTH faculty is made up ofinternational leaders in hematology who cover biostatisticsand biomarkers, genetics and molecular biology, ethics,and phase I clinical study design.

- EHA-ISTH Joint FellowshipThe EHA-ISTH Joint Fellowship is a collaborative programbetween EHA and the International Society of Thrombosisand Haemostasis. It is intended to support the study ofphysiology of coagulation, bleeding or thrombosis.Award: €50K/year for two years

- EHA-JSH Fellowship Exchange programThe EHA-JSH Collaborative Exchange Program is intendedto provide European and Japanese research institutes theopportunity to exchange basic scientists, clinicalresearchers and clinicians reciprocally for a short period(up to 4 months).Award: €10.000 or JPY 1,000,000

- NEW! Advanced Short Term Collaboration AwardEHA introduces short term support to encourage mobilityfor established hematologists (clinical, scientific oracademic), wishing to spend some time in a differentacademic hematological environment. The objective is tohelp with the additional financial burden involved in shortterm “sabbatical-style” mobility. The duration can be for aminimum of two months up to nine months. The call forapplications for 2015 is now open!

- NEW! Junior Short Term Collaboration AwardEHA’s Junior Short Term Collaboration Award supports the

56

career development of young scientists who are involved inbasic and/or clinical research in hematology. The JuniorShort Term Collaboration Award creates the opportunity forthose young scientists to work at a host institute for amaximum period of three months. The aim of the programis to facilitate the collaboration with research groups thathave techniques or facilities that are unavailable in theapplicant’s home institute. Fellows working in the hostinstitute also facilitate the development of a continuingcollaborative network between hematology institutes.

- Master ClassThe EHA Master Class is an online group learningexperience for hematologists nearing completion of theirtraining. The goal of the Master Class is o developprofessional behavior and long-term skill sets inHematology in order to enhance professional practice andmobility.

- Bite Size Master Class The Bite Size Master Class builds on the experience andstrengths of the full-length Master Class, but will allow formore time flexibility. It will give the opportunity tospecifically target educational gaps by offering only oneproblem-based exercise focusing on a single CurriculumPassport topic over a period of six weeks. The Bite SizeMaster Class will be held in February and October onvarious topics for both junior as senior hematologists.

COMPLETE THE COMPETENCE SURVEY – CONTRIBUTETO HARMONIZATION OF HEMATOLOGY IN EUROPE!In order to identify areas in hematology training andeducation needing further improvement, EHA launched theEuropean Competence Survey. During the first months, over200 hematologists from 26 countries participated, andparticipation is still possible.The results of the survey will provide evidence for thoseresponsible for hematology training and education to furtherdevelop their program in targeted areas of need. Furthermore,the results of the survey will help reinforce the position ofhematology in the political arena. As a participant, you will also benefit at an individual level.Your answers can be transferred to the personal Online CVPassport, which you can use to monitor personalcompetences, skills, and knowledge over time and comparethese with other European hematologists.Targeted participants for the competence survey arehematologists who recently completed their training andthose at the end of their training. If you are a seniorhematologist, you can also support this important initiative,by disseminating the message amongst yourcolleagues/fellows.

e h a w e b . o r g 57

EHA Research FellowshipsClinical Research Fellowships

For clinicians with a PhD or equivalent research experience who wish to consolidate their research training or who are establishing their own independent research groups.Award: €80K/year for three years

Non-Clinical Junior Research FellowshipsFor non-medical scientists with 1 – 4 years of postdoctoral experience.Best application is awarded the José Carreras Non-Clinical Junior FellowshipAward: €50K/year for three years

Non-Clinical Advanced Research FellowshipsFor non-medical scientists with 4 years of postdoctoral experience.Award: €80K/year for three years

EHA EARLY CAREER OPPORTUNITIES

NEW! Advanced Short Term Collaboration AwardEHA introduces short term support to encourage mobility for established hematologists (clinical,scientific or academic), wishing to spend some time in a different academic hematologicalenvironment. The objective is to help with the additional financial burden involved in short term“sabbatical-style” mobility. The duration can be for a minimum of two months up to nine months. Thecall for applications for 2015 is now open!

NEW! Junior Short Term Collaboration AwardEHA’s Junior Short Term Collaboration Award supports the career development of young scientistswho are involved in basic and/or clinical research in hematology. The Junior Short Term CollaborationAward creates the opportunity for those young scientists to work at a host institute for a maximumperiod of three months. The aim of the program is to facilitate the collaboration with research groupsthat have techniques or facilities that are unavailable in the applicant’s home institute. Fellows workingin the host institute also facilitate the development of a continuing collaborative network betweenhematology institutes.